TransporterID	Gene_name	MOA	phenotype	regulation_phenomenon	class	Regulating_factor_type	factor_uniform_name	Source	SpeciesName32	strain_subname	in vivo_1	in vitro_1	Description_all	Related_drugs	Tissue
DTD0036	ABCA1	Up regulating	Atherosclerosis	Up regulating of ABCA1 expression in atherosclerosis condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	3,4-Dihydroxybenzoic acid	Dietary cyanidin-3-O--glucoside metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite 3,4-dihydroxybenzoic acid generated from the metabolism of dietary cyanidin-3-o--glucoside by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCA1.	.	Blood
DTD0036	ABCA1	Up regulating	.	Up regulating of ABCA1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Trimethylamine oxide	L-carnitine metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCA1.	.	Liver
DTD0003	ABCB1	Down regulating	Colon adenocarcinoma	Down regulating of ABCB1 expression in colon adenocarcinoma condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus murinus	Ligilactobacillus murinus	Ligilactobacillus murinus	.	Sprague-Dawley specific pathogen free rats	Human colon adenocarcinoma cells (Caco-2)	The Ligilactobacillus murinus has been reported to decrease the expression of the drug transporter ABCB1.	Glycyrrhizic Acid	Colon
DTD0003	ABCB1	Down regulating	Colon adenocarcinoma	Down regulating of ABCB1 expression in colon adenocarcinoma condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Salmonella enterica subsp. enterica serovar Typhimurium	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium	.	Madin-Darby canine kidney cells (MDCKII)	The Salmonella enterica subsp. enterica serovar Typhimurium has been reported to decrease the expression of the drug transporter ABCB1.	Digoxin	Colon
DTD0003	ABCB1	Sequestration substrate	.	Sequestration of human ABCB1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	str. K-12 substr. MG1655	.	.	The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Chloramphenicol and Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter ABCB1, thereby affecting the efficacy, safety, or bioavailability of the drug.	Chloramphenicol; Tetracycline	.
DTD0003	ABCB1	Co-transporter	.	Co-transport of human ABCB1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhi 1895	.	.	The protein ompF of Salmonella enterica subsp. enterica serovar Typhi 1895 has been reported to transport similar substrates/drugs of ABCB1, which affects the distribution of its substrate/drug in vivo.	Chloramphenicol	.
DTD0003	ABCB1	Co-transporter	.	Co-transport of human ABCB1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of ABCB1, which affects the distribution of its substrate/drug in vivo.	Norfloxacin; Tetracycline; Chloramphenicol	.
DTD0003	ABCB1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCB1 expression in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	3-Indolepropionic acid; L-tryptophan	Indole metabolite from Clostridium sporogenes	Clostridium sporogenes	.	Swiss Webster germ-free mice	Human kidney human embryonic kidney 293T cells (HEK 293T)	The metabolite 3-indolepropionic acid and l-tryptophan generated from the metabolism of indole by the Clostridium sporogenes has been reported to increase the expression of the drug transporter ABCB1.	.	Small intestine
DTD0003	ABCB1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCB1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bacteroides thetaiotaomicron	Bacteroides thetaiotaomicron	Bacteroides thetaiotaomicron	.	Germ-free mice	.	The Bacteroides thetaiotaomicron has been reported to decrease the expression of the drug transporter ABCB1.	.	Intestine
DTD0003	ABCB1	Up regulating	Colon cancer	Up regulating of ABCB1 expression in colon cancer condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bifidobacterium adolescentis	Bifidobacterium adolescentis	Bifidobacterium adolescentis	.	.	Human colon adenocarcinoma cells (Caco-2)	The Bifidobacterium adolescentis has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Type 1 diabetes mellitus	Down regulating of ABCB1 expression in type 1 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Clostridium_sensu_stricto_1 isolates	Unclassified Clostridium	Unclassified Clostridium	stricto 1	Diabetic sprague-dawley rats	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Clostridium stricto 1 has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Up regulating	Colon cancer	Up regulating of ABCB1 expression in colon cancer condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli Nissle 1917	Escherichia coli	Escherichia coli	Nissle 1917	.	Human colon adenocarcinoma cells (Caco-2)	The Escherichia coli Nissle 1917 has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Type 1 diabetes mellitus	Down regulating of ABCB1 expression in type 1 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lachnoclostridium isolates(down)	Unclassified Lachnoclostridium	Unclassified Lachnoclostridium	.	Diabetic sprague-dawley rats	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Lachnoclostridium has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Type 1 diabetes mellitus	Down regulating of ABCB1 expression in type 1 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Prevotellaceae_NK3B31_group	Unclassified Prevotellaceae	Unclassified Prevotellaceae	.	Diabetic sprague-dawley rats	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Prevotellaceae has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Type 1 diabetes mellitus	Down regulating of ABCB1 expression in type 1 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Prevotellaceae_UCG-001	Unclassified Oscillospiraceae	Unclassified Oscillospiraceae	.	Diabetic sprague-dawley rats	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Oscillospiraceae has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Type 1 diabetes mellitus	Down regulating of ABCB1 expression in type 1 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Romboutsia isolates	Unclassified Romboutsia	Unclassified Romboutsia	.	Diabetic sprague-dawley rats	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Romboutsia has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Type 1 diabetes mellitus	Down regulating of ABCB1 expression in type 1 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Ruminococcaceae_UCG-005 isolates	Unclassified Oscillospiraceae	Unclassified Oscillospiraceae	.	Diabetic sprague-dawley rats	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Oscillospiraceae has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Type 1 diabetes mellitus	Down regulating of ABCB1 expression in type 1 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Turicibacter isolates	Unclassified Turicibacter	Unclassified Turicibacter	.	Diabetic sprague-dawley rats	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Turicibacter has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Type 1 diabetes mellitus	Down regulating of ABCB1 expression in type 1 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Unclassified_f_Prevotellaceae isolates	Unclassified Prevotellaceae	Unclassified Prevotellaceae	.	Diabetic sprague-dawley rats	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Prevotellaceae has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Eubacterium	Unclassified Eubacterium	Unclassified Eubacterium	.	C57BL/6J mice	Human lung mucoepidermoid carcinoma cells (NCI-H292)	The Unclassified Eubacterium has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus	Unclassified Lactobacillus	Unclassified Lactobacillus	.	C57BL/6J mice	Human lung mucoepidermoid carcinoma cells (NCI-H292)	The Unclassified Lactobacillus has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Inhibition	.	Inhibition of ABCB1 function in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Glycochenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite glycochenodeoxycholic acid generated from the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.	Salmon calcitonin	Intestine
DTD0003	ABCB1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCB1 expression in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	3-Indolepropionic acid	L-tryptophan metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J germ-free mice	.	The metabolite 3-indolepropionic acid generated from the metabolism of l-tryptophan by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Small intestine
DTD0003	ABCB1	Up regulating	Colon cancer	Up regulating of ABCB1 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (HT-29)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Up regulating	Colon cancer	Up regulating of ABCB1 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (HT-29)	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Inhibition	Colon cancer	Inhibition of ABCB1 function in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Sodium taurocholate	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco-2)	The metabolite sodium taurocholate generated from the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCB1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6N mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB1.	.	Small intestine
DTD0003	ABCB1	Up regulating	Hypoxia	Up regulating of ABCB1 expression in hypoxia condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Liver
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	3-Indolepropionic acid	L-tryptophan metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J conventionally-raised mice	.	The metabolite 3-indolepropionic acid generated from the metabolism of l-tryptophan by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Ileum
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	3-Indolepropionic acid	L-tryptophan metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J conventionally-raised mice	.	The metabolite 3-indolepropionic acid generated from the metabolism of l-tryptophan by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Jejunum
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Dietary food metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Human lung mucoepidermoid carcinoma cells (NCI-H292)	The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Mouse precursor T cell lymphoblastic lymphoma cells(EL4)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Ileum
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Cholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Mouse precursor T cell lymphoblastic lymphoma cells(EL4)	The metabolite cholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Ileum
DTD0003	ABCB1	Activation	.	Activation of ABCB1 function in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Human lung mucoepidermoid carcinoma cells (NCI-H292)	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to activate the function of the drug transporter ABCB1.	.	Lung
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Mouse precursor T cell lymphoblastic lymphoma cells(EL4)	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Ileum
DTD0003	ABCB1	Activation	.	Activation of ABCB1 function in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Lithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Human lung mucoepidermoid carcinoma cells (NCI-H292)	The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to activate the function of the drug transporter ABCB1.	.	Lung
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Lithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Human lung mucoepidermoid carcinoma cells (NCI-H292)	The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	L-Tryptophan	Dietary food metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J conventionally-raised mice	.	The metabolite l-tryptophan generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Duodenum
DTD0003	ABCB1	Inhibition	.	Inhibition of ABCB1 function in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Sodium 12-Oxochenodeoxycholate	Generated by Host unspecified microbiota	Host unspecified microbiota	.	.	Rat brain microvascular endothelial cells (RBE4)	The compound sodium 12-oxochenodeoxycholate generated by host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.	.	Brain
DTD0003	ABCB1	Inhibition	.	Inhibition of ABCB1 function in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Taurochenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite taurochenodeoxycholic acid generated from the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.	.	Intestine
DTD0003	ABCB1	Inhibition	.	Inhibition of ABCB1 function in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Taurolithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite taurolithocholic acid generated from the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCB1.	.	Intestine
DTD0003	ABCB1	Down regulating	.	Down regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Urolithin A	Dietary polyphenols metabolite from Host unspecified microbiota	Host unspecified microbiota	.	NRGS mice	Human colon carcinoma cells (HCT-116)	The metabolite urolithin a generated from the metabolism of dietary polyphenols by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB1.	.	Colon
DTD0003	ABCB1	Activation	.	Activation of ABCB1 function in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Ursodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Human lung mucoepidermoid carcinoma cells (NCI-H292)	The metabolite ursodeoxycholic acid generated from the host unspecified microbiota has been reported to activate the function of the drug transporter ABCB1.	.	Lung
DTD0003	ABCB1	Up regulating	.	Up regulating of ABCB1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Ursodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Human lung mucoepidermoid carcinoma cells (NCI-H292)	The metabolite ursodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB1.	.	Colon
DTD0014	ABCB11	Up regulating	Metabolic dysfunction-associated fatty liver disease	Up regulating of ABCB11 expression in metabolic dysfunction-associated fatty liver disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Akkermansia muciniphila	Akkermansia muciniphila	Akkermansia muciniphila	ATCC BAA-835	C57BL/6 mice	.	The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter ABCB11.	.	Liver
DTD0014	ABCB11	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCB11 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6N mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCB11.	.	Liver
DTD0014	ABCB11	Down regulating	.	Down regulating of ABCB11 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.	.	Liver
DTD0014	ABCB11	Down regulating	.	Down regulating of ABCB11 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.	.	Liver
DTD0014	ABCB11	Down regulating	.	Down regulating of ABCB11 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.	.	Liver
DTD0014	ABCB11	Down regulating	.	Down regulating of ABCB11 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.	.	Liver
DTD0014	ABCB11	Down regulating	.	Down regulating of ABCB11 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCB11.	.	Liver
DTD0056	ABCC10	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCC10 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC10.	.	Jejunum
DTD0056	ABCC10	Down regulating	.	Down regulating of ABCC10 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Urolithin A	Dietary polyphenols metabolite from Host unspecified microbiota	Host unspecified microbiota	.	NRGS mice	Human colon carcinoma cells (HCT-116)	The metabolite urolithin a generated from the metabolism of dietary polyphenols by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC10.	.	Colon
DTD0002	ABCC2	Up regulating	Diabetes	Up regulating of ABCC2 expression in diabetes condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bifidobacterium lactis	Bifidobacterium animalis	Bifidobacterium animalis	subsp. lactis	Sprague-Dawley rats	.	The Bifidobacterium animalis subsp. lactis has been reported to increase the expression of the drug transporter ABCC2.	Gliclazide	Ileum
DTD0002	ABCC2	Up regulating	Diabetes	Up regulating of ABCC2 expression in diabetes condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus acidophilus	Lactobacillus acidophilus	Lactobacillus acidophilus	.	Sprague-Dawley rats	.	The Lactobacillus acidophilus has been reported to increase the expression of the drug transporter ABCC2.	Gliclazide	Ileum
DTD0002	ABCC2	Down regulating	Colon adenocarcinoma	Down regulating of ABCC2 expression in colon adenocarcinoma condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus murinus	Ligilactobacillus murinus	Ligilactobacillus murinus	.	Sprague-Dawley specific pathogen free rats	Human colon adenocarcinoma cells (Caco-2)	The Ligilactobacillus murinus has been reported to decrease the expression of the drug transporter ABCC2.	Glycyrrhizic Acid	Colon
DTD0002	ABCC2	Up regulating	Diabetes	Up regulating of ABCC2 expression in diabetes condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus rhamnosus	Lacticaseibacillus rhamnosus	Lacticaseibacillus rhamnosus	.	Sprague-Dawley rats	.	The Lacticaseibacillus rhamnosus has been reported to increase the expression of the drug transporter ABCC2.	Gliclazide	Ileum
DTD0002	ABCC2	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCC2 expression in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	3-Indolepropionic acid; Indole	Indole metabolite from Clostridium sporogenes	Clostridium sporogenes	.	Swiss Webster germ-free mice	Human kidney human embryonic kidney 293T cells (HEK 293T)	The metabolite 3-indolepropionic acid and indole generated from the metabolism of indole by the Clostridium sporogenes has been reported to increase the expression of the drug transporter ABCC2.	.	Kidney
DTD0002	ABCC2	Up regulating	Metabolic dysfunction-associated fatty liver disease	Up regulating of ABCC2 expression in metabolic dysfunction-associated fatty liver disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Akkermansia muciniphila	Akkermansia muciniphila	Akkermansia muciniphila	ATCC BAA-835	C57BL/6 mice	.	The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter ABCC2.	.	Liver
DTD0002	ABCC2	Down regulating	Colon cancer	Down regulating of ABCC2 expression in colon cancer condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bifidobacterium adolescentis	Bifidobacterium adolescentis	Bifidobacterium adolescentis	.	.	Human colon adenocarcinoma cells (Caco-2)	The Bifidobacterium adolescentis has been reported to decrease the expression of the drug transporter ABCC2.	.	Colon
DTD0002	ABCC2	Down regulating	Colon cancer	Down regulating of ABCC2 expression in colon cancer condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli Nissle 1917	Escherichia coli	Escherichia coli	Nissle 1917	.	Human colon adenocarcinoma cells (Caco-2)	The Escherichia coli Nissle 1917 has been reported to decrease the expression of the drug transporter ABCC2.	.	Colon
DTD0002	ABCC2	Up regulating	Colon cancer	Up regulating of ABCC2 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco-2)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.	.	Colon
DTD0002	ABCC2	Up regulating	Colon cancer	Up regulating of ABCC2 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (HT-29)	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.	.	Colon
DTD0002	ABCC2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCC2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6N mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.	.	Small intestine
DTD0002	ABCC2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCC2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.	.	Jejunum
DTD0002	ABCC2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCC2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.	.	Liver
DTD0002	ABCC2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCC2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.	.	Jejunum
DTD0002	ABCC2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCC2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J germ-free mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.	.	Liver
DTD0002	ABCC2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCC2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.	.	Ileum
DTD0002	ABCC2	Down regulating	.	Down regulating of ABCC2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	2,3,7,8-tetrachlorodibenzofuran	Dietary dough pills metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite 2,3,7,8-tetrachlorodibenzofuran generated from the metabolism of dietary dough pills by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.	.	Ileum
DTD0002	ABCC2	Up regulating	.	Up regulating of ABCC2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.	.	Liver
DTD0002	ABCC2	Up regulating	.	Up regulating of ABCC2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.	.	Liver
DTD0002	ABCC2	Up regulating	.	Up regulating of ABCC2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.	.	Liver
DTD0002	ABCC2	Up regulating	.	Up regulating of ABCC2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.	.	Liver
DTD0002	ABCC2	Up regulating	.	Up regulating of ABCC2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC2.	.	Liver
DTD0002	ABCC2	Down regulating	.	Down regulating of ABCC2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Urolithin A	Dietary polyphenols metabolite from Host unspecified microbiota	Host unspecified microbiota	.	NRGS mice	Human colon carcinoma cells (HCT-116)	The metabolite urolithin a generated from the metabolism of dietary polyphenols by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC2.	.	Colon
DTD0012	ABCC3	Up regulating	Metabolic dysfunction-associated fatty liver disease	Up regulating of ABCC3 expression in metabolic dysfunction-associated fatty liver disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Akkermansia muciniphila	Akkermansia muciniphila	Akkermansia muciniphila	ATCC BAA-835	C57BL/6 mice	.	The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter ABCC3.	.	Liver
DTD0012	ABCC3	Up regulating	Colon cancer	Up regulating of ABCC3 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (HT-29)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Colon
DTD0012	ABCC3	Up regulating	Colon cancer	Up regulating of ABCC3 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco-2)	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Colon
DTD0012	ABCC3	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCC3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free/specific-pathogen-free mice	Mouse leukemia cells (RAW 264.7)	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Colon
DTD0012	ABCC3	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCC3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Ileum
DTD0012	ABCC3	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCC3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Liver
DTD0012	ABCC3	Up regulating	.	Up regulating of ABCC3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	2,3,7,8-tetrachlorodibenzofuran	Dietary dough pills metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite 2,3,7,8-tetrachlorodibenzofuran generated from the metabolism of dietary dough pills by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Ileum
DTD0012	ABCC3	Up regulating	.	Up regulating of ABCC3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	2,3,7,8-tetrachlorodibenzofuran	Dietary dough pills metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite 2,3,7,8-tetrachlorodibenzofuran generated from the metabolism of dietary dough pills by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Liver
DTD0012	ABCC3	Up regulating	.	Up regulating of ABCC3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Ileum
DTD0012	ABCC3	Up regulating	.	Up regulating of ABCC3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Ileum
DTD0012	ABCC3	Up regulating	.	Up regulating of ABCC3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Ileum
DTD0012	ABCC3	Up regulating	.	Up regulating of ABCC3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Ileum
DTD0012	ABCC3	Up regulating	.	Up regulating of ABCC3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Ileum
DTD0012	ABCC3	Up regulating	.	Up regulating of ABCC3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Lithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC3.	.	Liver
DTD0015	ABCC4	Sequestration substrate	.	Sequestration of human ABCC4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	str. K-12 substr. MG1655	.	.	The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Ciprofloxacin, which limits the distribution of the drug in the body and its binding to the drug transporter ABCC4, thereby affecting the efficacy, safety, or bioavailability of the drug.	Ciprofloxacin	.
DTD0015	ABCC4	Inhibition	Chronic kidney disease	Inhibition of ABCC4 function in chronic kidney disease condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	p-Cresol glucuronide	p-cresol metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human renal proximal tubule cells	The metabolite p-cresol glucuronide generated from the metabolism of p-cresol by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCC4.	.	Kidney
DTD0015	ABCC4	Inhibition	Chronic kidney disease	Inhibition of ABCC4 function in chronic kidney disease condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	p-Cresol sulfate	p-cresol metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human renal proximal tubule cells	The metabolite p-cresol sulfate generated from the metabolism of p-cresol by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCC4.	.	Kidney
DTD0015	ABCC4	Up regulating	Hyperuricaemia	Up regulating of ABCC4 expression in hyperuricaemia condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	ICR specific-pathogen-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.	.	Kidney
DTD0015	ABCC4	Up regulating	.	Up regulating of ABCC4 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.	.	Liver
DTD0015	ABCC4	Up regulating	.	Up regulating of ABCC4 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.	.	Liver
DTD0015	ABCC4	Up regulating	.	Up regulating of ABCC4 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.	.	Liver
DTD0015	ABCC4	Up regulating	.	Up regulating of ABCC4 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.	.	Liver
DTD0015	ABCC4	Up regulating	.	Up regulating of ABCC4 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC4.	.	Liver
DTD0016	ABCC5	Up regulating	.	Up regulating of ABCC5 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.	.	Liver
DTD0016	ABCC5	Up regulating	.	Up regulating of ABCC5 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.	.	Liver
DTD0016	ABCC5	Up regulating	.	Up regulating of ABCC5 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.	.	Liver
DTD0016	ABCC5	Up regulating	.	Up regulating of ABCC5 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.	.	Liver
DTD0016	ABCC5	Up regulating	.	Up regulating of ABCC5 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC5.	.	Liver
DTD0017	ABCC6	Down regulating	Conventional mice compared with germ-free mice	Down regulating of ABCC6 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC6.	.	Large intestine
DTD0017	ABCC6	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCC6 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCC6.	.	Ileum
DTD0017	ABCC6	Down regulating	.	Down regulating of ABCC6 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Trimethylamine oxide	L-carnitine metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC6.	.	Liver
DTD0060	ABCC7	Activation	Typhoid	Activation of ABCC7 in typhoid condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhi str. Ty2	C57BL/6 mice	Human cystic fibrosis cells (CFT1-LCFSN)	The compound Lipopolysaccharide Generated by Salmonella enterica subsp. enterica serovar Typhi str. Ty2 has been reported to activate the function of the drug transporter ABCC7.	.	Lung
DTD0060	ABCC7	Up regulating	Mastitis	Up regulating of ABCC7 expression in mastitis condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	O111:B4	ICR mice	.	The compound Lipopolysaccharide Generated by Escherichia coli O111:B4 has been reported to increase the expression of the drug transporter ABCC7.	.	Breast
DTD0060	ABCC7	Up regulating	Diarrhea associated with infection by invasive enteric pathogens	Up regulating of ABCC7 expression in diarrhea associated with infection by invasive enteric pathogens condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	O29	.	Human colon adenocarcinoma cells (HT29-Cl.19A)	The Escherichia coli O29 has been reported to increase the expression of the drug transporter ABCC7.	.	Colon
DTD0060	ABCC7	Up regulating	Type 2 diabetes mellitus	Up regulating of ABCC7 expression in type 2 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus casei	Lacticaseibacillus casei	Lacticaseibacillus casei	str. Zhang	Sprague-Dawley rats	.	The Lacticaseibacillus casei str. Zhang has been reported to increase the expression of the drug transporter ABCC7.	.	Heart
DTD0060	ABCC7	Up regulating	Diarrhea associated with infection by invasive enteric pathogens	Up regulating of ABCC7 expression in diarrhea associated with infection by invasive enteric pathogens condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Salmonella dublin	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Dublin	.	Human colon adenocarcinoma cells (HT29-Cl.19A)	The Salmonella enterica subsp. enterica serovar Dublin has been reported to increase the expression of the drug transporter ABCC7.	.	Colon
DTD0060	ABCC7	Down regulating	Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli	Down regulating of ABCC7 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	C57BL/6 microflora	Host unspecified microbiota	Host unspecified microbiota	.	FVB/N mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC7.	.	Colon
DTD0060	ABCC7	Down regulating	.	Down regulating of ABCC7 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Trimethylamine oxide	L-carnitine metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCC7.	.	Liver
DTD0071	ABCG1	Up regulating	Atherosclerosis	Up regulating of ABCG1 expression in atherosclerosis condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	3,4-Dihydroxybenzoic acid	Dietary cyanidin-3-O--glucoside metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 3,4-dihydroxybenzoic acid generated from the metabolism of dietary cyanidin-3-o--glucoside by the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCG1.	.	Kidney
DTD0004	ABCG2	Sequestration substrate	.	Sequestration of human ABCG2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Bacteroides thetaiotaomicron	Bacteroides thetaiotaomicron	Bacteroides thetaiotaomicron	E50	.	.	The Bacteroides thetaiotaomicron E50 has been reported to sequester the drug Rosiglitazone, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Rosiglitazone	.
DTD0004	ABCG2	Sequestration substrate	.	Sequestration of human ABCG2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Bifidobacterium animalis subsp. lactis	Bifidobacterium animalis	Bifidobacterium animalis	subsp. lactis Bi-07	.	.	The Bifidobacterium animalis subsp. lactis Bi-07 has been reported to sequester the drug Rosiglitazone, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Rosiglitazone	.
DTD0004	ABCG2	Sequestration substrate	.	Sequestration of human ABCG2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Clostridium ramosum	Thomasclavelia ramosa	Thomasclavelia ramosa	113-I	.	.	The Thomasclavelia ramosa 113-I has been reported to sequester the drug Rosiglitazone, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Rosiglitazone	.
DTD0004	ABCG2	Sequestration substrate	.	Sequestration of human ABCG2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	str. K-12 substr. MG1655	.	.	The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Ciprofloxacin and Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Ciprofloxacin; Tetracycline	.
DTD0004	ABCG2	Sequestration substrate	.	Sequestration of human ABCG2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Lactobacillus paracasei	Lacticaseibacillus casei	Lacticaseibacillus casei	Lpc-37	.	.	The Lacticaseibacillus casei Lpc-37 has been reported to sequester the drug Rosiglitazone, which limits the distribution of the drug in the body and its binding to the drug transporter ABCG2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Rosiglitazone	.
DTD0004	ABCG2	Co-transporter	.	Co-transport of human ABCG2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompC	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompC of Escherichia coli JM712 has been reported to transport similar substrates/drugs of ABCG2, which affects the distribution of its substrate/drug in vivo.	Cephalothin	.
DTD0004	ABCG2	Co-transporter	.	Co-transport of human ABCG2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of ABCG2, which affects the distribution of its substrate/drug in vivo.	Norfloxacin; Tetracycline; Cephalothin	.
DTD0004	ABCG2	Down regulating	Colon cancer	Down regulating of ABCG2 expression in colon cancer condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bifidobacterium adolescentis	Bifidobacterium adolescentis	Bifidobacterium adolescentis	.	.	Human colon adenocarcinoma cells (Caco-2)	The Bifidobacterium adolescentis has been reported to decrease the expression of the drug transporter ABCG2.	.	Colon
DTD0004	ABCG2	Down regulating	Colon cancer	Down regulating of ABCG2 expression in colon cancer condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli Nissle 1917	Escherichia coli	Escherichia coli	Nissle 1917	.	Human colon adenocarcinoma cells (Caco-2)	The Escherichia coli Nissle 1917 has been reported to decrease the expression of the drug transporter ABCG2.	.	Colon
DTD0004	ABCG2	Inhibition	Health	Inhibition of ABCG2 function in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Urolithin A	Ellagic acid and ellagitannins metabolites from gut Host unspecified microbiota	Host unspecified microbiota	.	.	Madin-Darby canine kidney cells (MDCKII)	The metabolite urolithin a generated from the metabolism of ellagic acid and ellagitannins metabolites from gut host unspecified microbiota by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCG2.	Mitoxantrone	Kidney
DTD0004	ABCG2	Inhibition	Health	Inhibition of ABCG2 function in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Urolithin A glucuronide	Ellagic acid and ellagitannins metabolites from gut Host unspecified microbiota	Host unspecified microbiota	.	.	Madin-Darby canine kidney cells (MDCKII)	The metabolite urolithin a glucuronide generated from the metabolism of ellagic acid and ellagitannins metabolites from gut host unspecified microbiota by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCG2.	Mitoxantrone	Kidney
DTD0004	ABCG2	Down regulating	Colon cancer	Down regulating of ABCG2 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (T84)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCG2.	.	Colon
DTD0004	ABCG2	Up regulating	Colon cancer	Up regulating of ABCG2 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco-2)	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter ABCG2.	.	Colon
DTD0004	ABCG2	Inhibition	Chronic kidney disease	Inhibition of ABCG2 function in chronic kidney disease condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	p-Cresol sulfate	p-cresol metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human renal proximal tubule cells	The metabolite p-cresol sulfate generated from the metabolism of p-cresol by the host unspecified microbiota has been reported to inhibit the function of the drug transporter ABCG2.	.	Kidney
DTD0004	ABCG2	Up regulating	Conventional mice compared with germ-free mice	Up regulating of ABCG2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6N mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCG2.	.	Liver
DTD0004	ABCG2	Up regulating	Hyperuricaemia	Up regulating of ABCG2 expression in hyperuricaemia condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	ICR specific-pathogen-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter ABCG2.	.	Kidney
DTD0004	ABCG2	Down regulating	.	Down regulating of ABCG2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Urolithin A	Dietary polyphenols metabolite from Host unspecified microbiota	Host unspecified microbiota	.	NRGS mice	Human colon carcinoma cells (HCT-116)	The metabolite urolithin a generated from the metabolism of dietary polyphenols by the host unspecified microbiota has been reported to decrease the expression of the drug transporter ABCG2.	.	Colon
DTD0648	ATP7A	Sequestration substrate	.	Sequestration of human ATP7A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	copA	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein copA of Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.	.	.
DTD0648	ATP7A	Sequestration substrate	.	Sequestration of human ATP7A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	copZ1	Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The protein copZ1 of Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.	.	.
DTD0648	ATP7A	Sequestration substrate	.	Sequestration of human ATP7A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	corA	Rhodobacter capsulatus	Rhodobacter capsulatus	MT1131	.	.	The protein corA of Rhodobacter capsulatus MT1131 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.	.	.
DTD0648	ATP7A	Sequestration substrate	.	Sequestration of human ATP7A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	corZ	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein corZ of Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.	.	.
DTD0648	ATP7A	Co-transporter	.	Co-transport of human ATP7A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctpV	Mycobacterium tuberculosis	Mycobacterium tuberculosis	GC1237	.	.	The protein ctpV of Mycobacterium tuberculosis GC1237 has been reported to transport similar substrates/drugs of ATP7A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0648	ATP7A	Sequestration substrate	.	Sequestration of human ATP7A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cupA	Streptococcus pneumoniae	Streptococcus pneumoniae	TIGR4	.	.	The protein cupA of Streptococcus pneumoniae TIGR4 has been reported to sequester the substrate/drug of ATP7A, which may affects its substrate/drug distribution in the body.	.	.
DTD0533	ATP7B	Sequestration substrate	.	Sequestration of human ATP7B substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	copA	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein copA of Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.	.	.
DTD0533	ATP7B	Sequestration substrate	.	Sequestration of human ATP7B substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	copZ1	Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The protein copZ1 of Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.	.	.
DTD0533	ATP7B	Sequestration substrate	.	Sequestration of human ATP7B substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	corA	Rhodobacter capsulatus	Rhodobacter capsulatus	MT1131	.	.	The protein corA of Rhodobacter capsulatus MT1131 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.	.	.
DTD0533	ATP7B	Sequestration substrate	.	Sequestration of human ATP7B substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	corZ	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein corZ of Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.	.	.
DTD0533	ATP7B	Co-transporter	.	Co-transport of human ATP7B substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctpV	Mycobacterium tuberculosis	Mycobacterium tuberculosis	GC1237	.	.	The protein ctpV of Mycobacterium tuberculosis GC1237 has been reported to transport similar substrates/drugs of ATP7B, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0533	ATP7B	Sequestration substrate	.	Sequestration of human ATP7B substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cupA	Streptococcus pneumoniae	Streptococcus pneumoniae	TIGR4	.	.	The protein cupA of Streptococcus pneumoniae TIGR4 has been reported to sequester the substrate/drug of ATP7B, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	Cystic fibrosis	Sequestration of human CACNA1A substrates/drugs in cystic fibrosis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyochelin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	ATCC 15692	CD-1 mice	.	The compound Pyochelin Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0518	CACNA1A	Sequestration substrate	Cystic fibrosis	Sequestration of human CACNA1A substrates/drugs in cystic fibrosis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyoverdine F-Iib	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	ATCC 15692	CD-1 mice	.	The compound Pyoverdine F-Iib Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0518	CACNA1A	Sequestration substrate	Lung adenocarcinoma	Sequestration of human CACNA1A substrates/drugs in lung adenocarcinoma condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KP20	.	Human lung adenocarcinoma cells (A549)	The compound Salmochelin SX Secreted by Klebsiella pneumoniae KP20 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0518	CACNA1A	Sequestration substrate	Pneumonia	Sequestration of human CACNA1A substrates/drugs in pneumonia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	ATCC 43816	C57BL/6 mice	.	The compound Yersiniabactin Secreted by Klebsiella pneumoniae ATCC 43816 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0518	CACNA1A	Co-transporter	Pneumonic plague	Co-transport of human CACNA1A substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Intestine
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Intestine
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KPPR1	C57BL/6 mice	.	The compound Salmochelin SX Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KPPR1	C57BL/6 mice	.	The compound Yersiniabactin Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	irp2	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein irp2 of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	psn	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeAB	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 2-oxoadipic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 2-oxoadipic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 2-oxoadipic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 2-oxoadipic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 2-Oxoadipic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 2-Oxoadipic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 2-Oxoadipic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Aerobactin	Secreted by Escherichia coli	Escherichia coli	LG1315	.	.	The compound Aerobactin Secreted by Escherichia coli LG1315 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Achromobacter xylosoxidans	Achromobacter xylosoxidans	subsp. xylosoxydans KN 3-1	.	.	The compound Alcaligin Secreted by Achromobacter xylosoxidans subsp. xylosoxydans KN 3-1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Bordetella bronchiseptica	Bordetella bronchiseptica	B013N	.	.	The compound Alcaligin Secreted by Bordetella bronchiseptica B013N has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Bordetella pertussis	Bordetella pertussis	UT25	.	.	The compound Alcaligin Secreted by Bordetella pertussis UT25 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Anguibactin	Secreted by Vibrio anguillarum	Vibrio anguillarum	775	.	.	The compound anguibactin secreted by Vibrio anguillarum 775 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Aureochelin	Secreted by Staphylococcus aureus	Staphylococcus aureus	.	.	.	The compound aureochelin secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Carboxymycobactin	Secreted by Mycobacterium avium	Mycobacterium avium	CRl/69	.	.	The compound Carboxymycobactin Secreted by Mycobacterium avium CRl/69 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Cepabactin	Secreted by Burkholderia cepacia	Burkholderia cepacia	ATCC 25416	.	.	The compound Cepabactin Secreted by Burkholderia cepacia ATCC 25416 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Corynebacterium diphtheriae	Corynebacterium diphtheriae	C7 (beta)	.	.	The compound Corynebactin Secreted by Corynebacterium diphtheriae C7 (beta) has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The compound Corynebactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus thuringiensis	Bacillus thuringiensis	ATCC 33679	.	.	The compound Corynebactin Secreted by Bacillus thuringiensis ATCC 33679 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The compound Corynebactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	BW25113	.	.	The compound Enterobactin Secreted by Escherichia coli BW25113 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The compound Enterobactin Secreted by Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. LT2	.	.	The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	298/53	.	.	The compound Enterobactin Secreted by Klebsiella pneumoniae 298/53 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Shigella sonnei	Shigella sonnei	43-GG9	.	.	The compound Enterobactin Secreted by Shigella sonnei 43-GG9 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	9.0111	.	.	The compound enterobactin secreted by Escherichia coli 9.0111 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	AB33II	.	.	The compound Enterobactin Secreted by Escherichia coli AB33II has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Exochelin 772SM	Secreted by Mycolicibacterium vaccae	Mycolicibacterium vaccae	R877R	.	.	The compound Exochelin 772SM Secreted by Mycolicibacterium vaccae R877R has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine B	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine E	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine G1	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound indole-3-pyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound indole-3-pyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound indole-3-pyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound indole-3-pyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound Indole-3-pyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound Indole-3-pyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound Indole-3-pyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ornibactin	Secreted by Burkholderia cepacia	Burkholderia cepacia	TVV69	.	.	The compound Ornibactin Secreted by Burkholderia cepacia TVV69 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Petrobactin	Secreted by Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The compound Petrobactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Petrobactin	Secreted by Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The compound Petrobactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound phenylpyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound phenylpyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound phenylpyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound phenylpyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound Phenylpyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound Phenylpyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound Phenylpyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyochelin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The compound Pyochelin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyoverdin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The compound Pyoverdin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Rhizoferrin	Secreted by Rhizopus microsporus	Rhizopus microsporus	.	.	.	The compound rhizoferrin secreted by Rhizopus microsporus has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salicylic acid	Secreted by Burkholderia cepacia	Burkholderia cepacia	Pc275c	.	.	The compound Salicylic acid Secreted by Burkholderia cepacia Pc275c has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. LT2	.	.	The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphyloferrin A	Secreted by Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The compound Staphyloferrin A Secreted by Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphylopine	Secreted by Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The compound Staphylopine Secreted by Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Vibriobactin	Secreted by Vibrio cholerae	Vibrio cholerae	Lou15	.	.	The compound Vibriobactin Secreted by Vibrio cholerae Lou15 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Vibriobactin	Secreted by Vibrio cholerae	Vibrio cholerae	MBG14	.	.	The compound Vibriobactin Secreted by Vibrio cholerae MBG14 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia pestis	Yersinia pestis	Yreka F1+VW+P1+P+	.	.	The compound Yersiniabactin Secreted by Yersinia pestis Yreka F1+VW+P1+P+ has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The compound Yersiniabactin Secreted by Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CaFTR1	Candida albicans	Candida albicans	.	.	.	The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	O157:H7	.	.	The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatA	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatB	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Fbp	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fec	Shigella flexneri	Shigella flexneri	2a	.	.	The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fecA	Escherichia coli	Escherichia coli	UT5600	.	.	The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Klebsiella pneumoniae	Klebsiella pneumoniae	.	.	.	The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuA	Escherichia coli	Escherichia coli	K-12	.	.	The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuB	Escherichia coli	Escherichia coli	DH5[alpha]	.	.	The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuC	Escherichia coli	Escherichia coli	AB2847	.	.	The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCBG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Streptococcus agalactiae	Streptococcus agalactiae	A909	.	.	The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Haemophilus influenzae	Haemophilus influenzae	R2866	.	.	The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD1	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN2564	.	.	The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA1	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA2	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futB	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IroA	Escherichia coli	Escherichia coli	CFT073	.	.	The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IrtAB	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuA	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuB	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuC	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sitA	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium JF2043	.	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0518	CACNA1A	Sequestration substrate	.	Sequestration of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sll1878	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of CACNA1A, which may affects its substrate/drug distribution in the body.	.	.
DTD0518	CACNA1A	Co-transporter	.	Co-transport of human CACNA1A substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM5-2031.11+	.	.	The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of CACNA1A, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0534	CACNA1C	Sequestration substrate	Upper and lower airway disease	Sequestration of human CACNA1C substrates/drugs in upper and lower airway disease condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. equi NCTC 9682	Swiss Webster mice	.	The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of CACNA1C, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0534	CACNA1C	Co-transporter	.	Co-transport of human CACNA1C substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mnoP	Bradyrhizobium diazoefficiens	Bradyrhizobium diazoefficiens	USDA 110	.	.	The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of CACNA1C, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0534	CACNA1C	Sequestration substrate	.	Sequestration of human CACNA1C substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. zooepidemicus NCTC 7023T	.	.	The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of CACNA1C, which may affects its substrate/drug distribution in the body.	.	.
DTD0019	SLC10A1	Up regulating	Metabolic dysfunction-associated fatty liver disease	Up regulating of SLC10A1 expression in metabolic dysfunction-associated fatty liver disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Akkermansia muciniphila	Akkermansia muciniphila	Akkermansia muciniphila	ATCC BAA-835	C57BL/6 mice	.	The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter SLC10A1.	.	Liver
DTD0019	SLC10A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC10A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A1.	.	Liver
DTD0019	SLC10A1	Down regulating	.	Down regulating of SLC10A1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A1.	.	Liver
DTD0019	SLC10A1	Up regulating	.	Up regulating of SLC10A1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Lithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	IQI mice	.	The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A1.	.	Liver
DTD0019	SLC10A1	Down regulating	.	Down regulating of SLC10A1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Trimethylamine oxide	L-carnitine metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A1.	.	Liver
DTD0020	SLC10A2	Down regulating	Health	Down regulating of SLC10A2 expression in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Glycoursodeoxycholic acid	Metabolite from Bacteroides fragilis	Bacteroides fragilis	.	.	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite glycoursodeoxycholic acid generated from the Bacteroides fragilis has been reported to decrease the expression of the drug transporter SLC10A2.	Metformin	Kidney
DTD0020	SLC10A2	Up regulating	Metabolic dysfunction-associated fatty liver disease	Up regulating of SLC10A2 expression in metabolic dysfunction-associated fatty liver disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Akkermansia muciniphila	Akkermansia muciniphila	Akkermansia muciniphila	ATCC BAA-835	C57BL/6 mice	.	The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC10A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC10A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Large intestine
DTD0020	SLC10A2	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC10A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.	.	Jejunum
DTD0020	SLC10A2	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC10A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.	.	Liver
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	2,3,7,8-tetrachlorodibenzofuran	Dietary dough pills metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite 2,3,7,8-tetrachlorodibenzofuran generated from the metabolism of dietary dough pills by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Colon
DTD0020	SLC10A2	Up regulating	.	Up regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.	.	Jejunum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Colon
DTD0020	SLC10A2	Up regulating	.	Up regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.	.	Jejunum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Colon
DTD0020	SLC10A2	Up regulating	.	Up regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.	.	Jejunum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Colon
DTD0020	SLC10A2	Up regulating	.	Up regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.	.	Jejunum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Colon
DTD0020	SLC10A2	Up regulating	.	Up regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC10A2.	.	Jejunum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Cyp8b1 KO mice	.	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Cholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Cyp8b1 KO mice	.	The metabolite cholic acid generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0020	SLC10A2	Down regulating	.	Down regulating of SLC10A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Cyp8b1 KO mice	.	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC10A2.	.	Ileum
DTD0080	SLC11A1	Co-transporter	Pneumonic plague	Co-transport of human SLC11A1 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Yersinia pestis	Yersinia pestis	.	Swiss Webster mice	.	The protein mnth of Yersinia pestis has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	Nose
DTD0080	SLC11A1	Sequestration substrate	.	Sequestration of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Mycobactin	Secreted by Mycobacterium avium	Mycobacterium avium	101	C57BL/6 mice	.	The compound mycobactin secreted by Mycobacterium avium 101 has been reported to sequester the substrate/drug of SLC11A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0080	SLC11A1	Sequestration substrate	.	Sequestration of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Mycobactin	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	C57BL/6 mice	.	The compound Mycobactin Secreted by Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC11A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0080	SLC11A1	Sequestration substrate	.	Sequestration of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Mycobactin	Secreted by Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	MC2 155	C57BL/6 mice	.	The compound Mycobactin Secreted by Mycolicibacterium smegmatis MC2 155 has been reported to sequester the substrate/drug of SLC11A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus str. Newman	C57BL/6 mice	.	The protein mntH of Staphylococcus aureus subsp. aureus str. Newman has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	Liver
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein mntH of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	Liver
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium	129/SvJ mice	.	The protein mntH of Salmonella enterica subsp. enterica serovar Typhimurium has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Brucella abortus	Brucella abortus	2308	C57BL/6 mice	.	The protein mnth of Brucella abortus 2308 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0080	SLC11A1	Sequestration substrate	.	Sequestration of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Mycobactin	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	.	.	.	The compound mycobactin secreted by Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC11A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Yersinia pseudotuberculosis	Yersinia pseudotuberculosis	IP 32953	.	.	The protein mntH of Yersinia pseudotuberculosis IP 32953 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Yersinia pestis	Yersinia pestis	KIM6	.	.	The protein mntH of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein mntH of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Escherichia coli	Escherichia coli	EMG2	.	.	The protein mntH of Escherichia coli EMG2 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Bradyrhizobium diazoefficiens	Bradyrhizobium diazoefficiens	USDA 110	.	.	The protein mntH of Bradyrhizobium diazoefficiens has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein mntH of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein mntH of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Mycobacterium leprae	Mycobacterium leprae	.	.	.	The protein mnth of Mycobacterium leprae has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Escherichia coli	Escherichia coli	MM1925	.	.	The protein mntH of Escherichia coli MM1925 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium MM1255	.	.	The protein mntH of Salmonella enterica subsp. enterica serovar Typhimurium MM1255 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Bacillus subtilis	Bacillus subtilis	CU1065	.	.	The protein mntH of Bacillus subtilis CU1065 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0080	SLC11A1	Co-transporter	.	Co-transport of human SLC11A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	nrmT	Clostridium acetobutylicum	Clostridium acetobutylicum	ATCC 824	.	.	The protein nrmT of Clostridium acetobutylicum ATCC 824 has been reported to transport similar substrates/drugs of SLC11A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC11A2 expression in conventional mice compared with germ-free mice	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	1,3-Diaminopropane	Generated by Lactobacillus reuteri	Limosilactobacillus reuteri	MM4-1A	C57BL/6 germ-free mice	Human colon carcinoma cells (HCT-116)	The compound 1,3-Diaminopropane Generated by Limosilactobacillus reuteri MM4-1A has been reported to decrease the expression of the drug transporter SLC11A2.	.	Duodenum
DTD0081	SLC11A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC11A2 expression in conventional mice compared with germ-free mice	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	3-Hydroxypropanal	Generated by Lactobacillus reuteri	Limosilactobacillus reuteri	MM4-1A	C57BL/6 germ-free mice	Human colon carcinoma cells (HCT-116)	The compound 3-Hydroxypropanal Generated by Limosilactobacillus reuteri MM4-1A has been reported to decrease the expression of the drug transporter SLC11A2.	.	Duodenum
DTD0081	SLC11A2	Sequestration substrate	Cystic fibrosis	Sequestration of human SLC11A2 substrates/drugs in cystic fibrosis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyochelin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	ATCC 15692	CD-1 mice	.	The compound Pyochelin Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Sequestration substrate	Cystic fibrosis	Sequestration of human SLC11A2 substrates/drugs in cystic fibrosis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyoverdine F-Iib	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	ATCC 15692	CD-1 mice	.	The compound Pyoverdine F-Iib Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Sequestration substrate	Lung adenocarcinoma	Sequestration of human SLC11A2 substrates/drugs in lung adenocarcinoma condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KP20	.	Human lung adenocarcinoma cells (A549)	The compound Salmochelin SX Secreted by Klebsiella pneumoniae KP20 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Sequestration substrate	Pneumonia	Sequestration of human SLC11A2 substrates/drugs in pneumonia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	ATCC 43816	C57BL/6 mice	.	The compound Yersiniabactin Secreted by Klebsiella pneumoniae ATCC 43816 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Co-transporter	Pneumonic plague	Co-transport of human SLC11A2 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0081	SLC11A2	Co-transporter	Bacterial pneumonia	Co-transport of human SLC11A2 substrates/drugs in bacterial pneumonia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MtsABC	Streptococcus pyogenes	Streptococcus pyogenes	AP1	BALB/c mice	.	The protein MtsABC of Streptococcus pyogenes AP1 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0081	SLC11A2	Sequestration substrate	Upper and lower airway disease	Sequestration of human SLC11A2 substrates/drugs in upper and lower airway disease condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. equi NCTC 9682	Swiss Webster mice	.	The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Co-transporter	Endocarditis	Co-transport of human SLC11A2 substrates/drugs in endocarditis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SloABC	Streptococcus mutans	Streptococcus mutans	V403	Endocarditis rats	.	The protein SloABC of Streptococcus mutans V403 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Heart
DTD0081	SLC11A2	Sequestration substrate	Sepsis	Sequestration of human SLC11A2 substrates/drugs in sepsis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Streptococcus suis	Streptococcus suis	serotype 9	CD-1 mice	.	The protein troA of Streptococcus suis serotype 9 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Liver
DTD0081	SLC11A2	Co-transporter	Pneumonic plague	Co-transport of human SLC11A2 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yfeA	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein yfeA of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Nose
DTD0081	SLC11A2	Co-transporter	Pneumonic plague	Co-transport of human SLC11A2 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	.	Swiss Webster mice	.	The protein yfeabcd of Yersinia pestis has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Nose
DTD0081	SLC11A2	Co-transporter	Pneumonic plague	Co-transport of human SLC11A2 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Nose
DTD0081	SLC11A2	Co-transporter	Cholera	Co-transport of human SLC11A2 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0081	SLC11A2	Co-transporter	Cholera	Co-transport of human SLC11A2 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Intestine
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Mycobactin	Secreted by Mycobacterium avium	Mycobacterium avium	101	C57BL/6 mice	.	The compound mycobactin secreted by Mycobacterium avium 101 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Mycobactin	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	C57BL/6 mice	.	The compound Mycobactin Secreted by Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Mycobactin	Secreted by Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	MC2 155	C57BL/6 mice	.	The compound Mycobactin Secreted by Mycolicibacterium smegmatis MC2 155 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Intestine
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KPPR1	C57BL/6 mice	.	The compound Salmochelin SX Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KPPR1	C57BL/6 mice	.	The compound Yersiniabactin Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fepD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	irp2	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein irp2 of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntA	Bacillus anthracis	Bacillus anthracis	str. Vollum	ICR mice	.	The protein mntA of Bacillus anthracis str. Vollum has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus str. Newman	C57BL/6 mice	.	The protein MntABC of Staphylococcus aureus subsp. aureus str. Newman has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Liver
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	psn	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Sit1p	Candida albicans	Candida albicans	CAF2-1	BALB/c mice	.	The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Liver
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium	129/SvJ mice	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeAB	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 2-oxoadipic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 2-oxoadipic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 2-oxoadipic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 2-oxoadipic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 2-Oxoadipic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 2-Oxoadipic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 2-Oxoadipic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Aerobactin	Secreted by Escherichia coli	Escherichia coli	LG1315	.	.	The compound Aerobactin Secreted by Escherichia coli LG1315 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Achromobacter xylosoxidans	Achromobacter xylosoxidans	subsp. xylosoxydans KN 3-1	.	.	The compound Alcaligin Secreted by Achromobacter xylosoxidans subsp. xylosoxydans KN 3-1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Bordetella bronchiseptica	Bordetella bronchiseptica	B013N	.	.	The compound Alcaligin Secreted by Bordetella bronchiseptica B013N has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Bordetella pertussis	Bordetella pertussis	UT25	.	.	The compound Alcaligin Secreted by Bordetella pertussis UT25 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Anguibactin	Secreted by Vibrio anguillarum	Vibrio anguillarum	775	.	.	The compound anguibactin secreted by Vibrio anguillarum 775 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Aureochelin	Secreted by Staphylococcus aureus	Staphylococcus aureus	.	.	.	The compound aureochelin secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Carboxymycobactin	Secreted by Mycobacterium avium	Mycobacterium avium	CRl/69	.	.	The compound Carboxymycobactin Secreted by Mycobacterium avium CRl/69 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Cepabactin	Secreted by Burkholderia cepacia	Burkholderia cepacia	ATCC 25416	.	.	The compound Cepabactin Secreted by Burkholderia cepacia ATCC 25416 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Corynebacterium diphtheriae	Corynebacterium diphtheriae	C7 (beta)	.	.	The compound Corynebactin Secreted by Corynebacterium diphtheriae C7 (beta) has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The compound Corynebactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus thuringiensis	Bacillus thuringiensis	ATCC 33679	.	.	The compound Corynebactin Secreted by Bacillus thuringiensis ATCC 33679 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The compound Corynebactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Desferriexochelin 772MS	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	str. Erdman	.	.	The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	BW25113	.	.	The compound Enterobactin Secreted by Escherichia coli BW25113 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The compound Enterobactin Secreted by Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. LT2	.	.	The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	298/53	.	.	The compound Enterobactin Secreted by Klebsiella pneumoniae 298/53 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Shigella sonnei	Shigella sonnei	43-GG9	.	.	The compound Enterobactin Secreted by Shigella sonnei 43-GG9 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	9.0111	.	.	The compound enterobactin secreted by Escherichia coli 9.0111 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	AB33II	.	.	The compound Enterobactin Secreted by Escherichia coli AB33II has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Exochelin 772SM	Secreted by Mycolicibacterium vaccae	Mycolicibacterium vaccae	R877R	.	.	The compound Exochelin 772SM Secreted by Mycolicibacterium vaccae R877R has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine B	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine E	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine G1	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound indole-3-pyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound indole-3-pyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound indole-3-pyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound indole-3-pyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound Indole-3-pyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound Indole-3-pyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound Indole-3-pyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Mycobactin	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	.	.	.	The compound mycobactin secreted by Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ornibactin	Secreted by Burkholderia cepacia	Burkholderia cepacia	TVV69	.	.	The compound Ornibactin Secreted by Burkholderia cepacia TVV69 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Petrobactin	Secreted by Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The compound Petrobactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Petrobactin	Secreted by Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The compound Petrobactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound phenylpyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound phenylpyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound phenylpyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound phenylpyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound Phenylpyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound Phenylpyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound Phenylpyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyochelin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The compound Pyochelin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyoverdin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The compound Pyoverdin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Rhizoferrin	Secreted by Rhizopus microsporus	Rhizopus microsporus	.	.	.	The compound rhizoferrin secreted by Rhizopus microsporus has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salicylic acid	Secreted by Burkholderia cepacia	Burkholderia cepacia	Pc275c	.	.	The compound Salicylic acid Secreted by Burkholderia cepacia Pc275c has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. LT2	.	.	The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphyloferrin A	Secreted by Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The compound Staphyloferrin A Secreted by Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphylopine	Secreted by Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The compound Staphylopine Secreted by Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Vibriobactin	Secreted by Vibrio cholerae	Vibrio cholerae	Lou15	.	.	The compound Vibriobactin Secreted by Vibrio cholerae Lou15 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Vibriobactin	Secreted by Vibrio cholerae	Vibrio cholerae	MBG14	.	.	The compound Vibriobactin Secreted by Vibrio cholerae MBG14 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia pestis	Yersinia pestis	Yreka F1+VW+P1+P+	.	.	The compound Yersiniabactin Secreted by Yersinia pestis Yreka F1+VW+P1+P+ has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The compound Yersiniabactin Secreted by Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CaFTR1	Candida albicans	Candida albicans	.	.	.	The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter coli	Campylobacter coli	W13A	.	.	The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	desA1	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efaA	Enterococcus faecalis	Enterococcus faecalis	JH2-2	.	.	The protein efaA of Enterococcus faecalis JH2-2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeO	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	O157:H7	.	.	The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatA	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatB	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Fbp	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fec	Shigella flexneri	Shigella flexneri	2a	.	.	The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fecA	Escherichia coli	Escherichia coli	UT5600	.	.	The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Klebsiella pneumoniae	Klebsiella pneumoniae	.	.	.	The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuA	Escherichia coli	Escherichia coli	K-12	.	.	The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuB	Escherichia coli	Escherichia coli	DH5[alpha]	.	.	The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuC	Escherichia coli	Escherichia coli	AB2847	.	.	The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCBG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Streptococcus agalactiae	Streptococcus agalactiae	A909	.	.	The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Haemophilus influenzae	Haemophilus influenzae	R2866	.	.	The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD1	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN2564	.	.	The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fimA	Streptococcus parasanguinis	Streptococcus parasanguinis	FW213	.	.	The protein fimA of Streptococcus parasanguinis FW213 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA1	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA2	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futB	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	GAPDH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	HtsABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IroA	Escherichia coli	Escherichia coli	CFT073	.	.	The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	iroN	Escherichia coli	Escherichia coli	O18:H7	.	.	The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IrtAB	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	BB	.	.	The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	N100	.	.	The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	FA19	.	.	The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mnoP	Bradyrhizobium diazoefficiens	Bradyrhizobium diazoefficiens	USDA 110	.	.	The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntA	Lactiplantibacillus plantarum	Lactiplantibacillus plantarum	subsp. plantarum ATCC 14917	.	.	The protein mntA of Lactiplantibacillus plantarum subsp. plantarum ATCC 14917 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Sinorhizobium meliloti	Sinorhizobium meliloti	242	.	.	The protein mntabc of Sinorhizobium meliloti 242 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABCD	Corynebacterium diphtheriae	Corynebacterium diphtheriae	C7 (beta)	.	.	The protein MntABCD of Corynebacterium diphtheriae C7 (beta) has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Escherichia coli	Escherichia coli	EMG2	.	.	The protein mntH of Escherichia coli EMG2 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein mntH of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. zooepidemicus NCTC 7023T	.	.	The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	psaA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein psaA of Streptococcus pneumoniae D39 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PsaABC	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein PsaABC of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0641	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0704	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv1872c	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ScaCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis substr. CH1	.	.	The protein ScaCBA of Streptococcus gordonii str. Challis substr. CH1 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	scaDMT	Staphylococcus capitis	Staphylococcus capitis	DSM 20326	.	.	The protein scaDMT of Staphylococcus capitis DSM 20326 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SfaABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuA	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuB	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuC	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SirABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus RN4220	.	.	The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sitA	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Rhizobium leguminosarum	Rhizobium leguminosarum	bv. viciae 3841	.	.	The protein SitABCD of Rhizobium leguminosarum bv. viciae 3841 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium MM1255	.	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium MM1255 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium JF2043	.	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sll1878	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SstABCD	Staphylococcus aureus	Staphylococcus aureus	W	.	.	The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbp1	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K199	.	.	The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	TonB1	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K1040	.	.	The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB3	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 19606	.	.	The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	138	.	.	The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	2	.	.	The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tssS	Yersinia pseudotuberculosis	Yersinia pseudotuberculosis	YPIII	.	.	The protein tssS of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Sequestration substrate	.	Sequestration of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tuf	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC11A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0081	SLC11A2	Co-transporter	.	Co-transport of human SLC11A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM5-2031.11+	.	.	The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC11A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0081	SLC11A2	Up regulating	Anemia	Up regulating of SLC11A2 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.	.	Colon
DTD0081	SLC11A2	Up regulating	Anemia	Up regulating of SLC11A2 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.	.	Duodenum
DTD0081	SLC11A2	Up regulating	Anemia	Up regulating of SLC11A2 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.	.	Colon
DTD0081	SLC11A2	Up regulating	Anemia	Up regulating of SLC11A2 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.	.	Duodenum
DTD0081	SLC11A2	Up regulating	Anemia	Up regulating of SLC11A2 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Propionate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.	.	Colon
DTD0081	SLC11A2	Up regulating	Anemia	Up regulating of SLC11A2 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Propionate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC11A2.	.	Duodenum
DTD0083	SLC12A2	Up regulating	Diarrhea associated with infection by invasive enteric pathogens	Up regulating of SLC12A2 expression in diarrhea associated with infection by invasive enteric pathogens condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	O29	.	Human colon adenocarcinoma cells (HT29-Cl.19A)	The Escherichia coli O29 has been reported to increase the expression of the drug transporter SLC12A2.	.	Colon
DTD0083	SLC12A2	Up regulating	Diarrhea associated with infection by invasive enteric pathogens	Up regulating of SLC12A2 expression in diarrhea associated with infection by invasive enteric pathogens condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Salmonella dublin	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Dublin	.	Human colon adenocarcinoma cells (HT29-Cl.19A)	The Salmonella enterica subsp. enterica serovar Dublin has been reported to increase the expression of the drug transporter SLC12A2.	.	Colon
DTD0091	SLC13A1	Co-transporter	Health	Co-transport of human SLC13A1 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	dcsT	Corynebacterium glutamicum	Corynebacterium glutamicum	ATCC 13032	.	.	The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A1, which affects the distribution of its substrate/drug in vivo.	Succinate; Fumarate; Malate	.
DTD0091	SLC13A1	Co-transporter	.	Co-transport of human SLC13A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VcINDY	Vibrio cholerae	Vibrio cholerae	AAF95939	.	.	The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0092	SLC13A2	Co-transporter	Health	Co-transport of human SLC13A2 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	dcsT	Corynebacterium glutamicum	Corynebacterium glutamicum	ATCC 13032	.	.	The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A2, which affects the distribution of its substrate/drug in vivo.	Succinate; Fumarate; Malate	.
DTD0092	SLC13A2	Co-transporter	.	Co-transport of human SLC13A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sdcS	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus Mu50	.	.	The protein sdcS of Staphylococcus aureus subsp. aureus Mu50 has been reported to transport similar substrates/drugs of SLC13A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0092	SLC13A2	Co-transporter	.	Co-transport of human SLC13A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VcINDY	Vibrio cholerae	Vibrio cholerae	AAF95939	.	.	The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0093	SLC13A3	Co-transporter	Health	Co-transport of human SLC13A3 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	dcsT	Corynebacterium glutamicum	Corynebacterium glutamicum	ATCC 13032	.	.	The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A3, which affects the distribution of its substrate/drug in vivo.	Succinate; Fumarate; Malate	.
DTD0093	SLC13A3	Co-transporter	.	Co-transport of human SLC13A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sdcS	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus Mu50	.	.	The protein sdcS of Staphylococcus aureus subsp. aureus Mu50 has been reported to transport similar substrates/drugs of SLC13A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0093	SLC13A3	Co-transporter	.	Co-transport of human SLC13A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VcINDY	Vibrio cholerae	Vibrio cholerae	AAF95939	.	.	The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0094	SLC13A4	Co-transporter	Health	Co-transport of human SLC13A4 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	dcsT	Corynebacterium glutamicum	Corynebacterium glutamicum	ATCC 13032	.	.	The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A4, which affects the distribution of its substrate/drug in vivo.	Succinate; Fumarate; Malate	.
DTD0094	SLC13A4	Co-transporter	.	Co-transport of human SLC13A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VcINDY	Vibrio cholerae	Vibrio cholerae	AAF95939	.	.	The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0095	SLC13A5	Co-transporter	Health	Co-transport of human SLC13A5 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	dcsT	Corynebacterium glutamicum	Corynebacterium glutamicum	ATCC 13032	.	.	The protein dcsT of Corynebacterium glutamicum ATCC 13032 has been reported to transport similar substrates/drugs of SLC13A5, which affects the distribution of its substrate/drug in vivo.	Succinate; Fumarate; Malate	.
DTD0095	SLC13A5	Co-transporter	.	Co-transport of human SLC13A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VcINDY	Vibrio cholerae	Vibrio cholerae	AAF95939	.	.	The protein VcINDY of Vibrio cholerae AAF95939 has been reported to transport similar substrates/drugs of SLC13A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompC	Escherichia coli	Escherichia coli	.	.	.	The protein ompc of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Dipeptide; Tripeptide; Peptidomimetic drugs	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompC	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompC of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Cefoxitin	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	.	.	.	The protein ompf of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Dipeptide; Tripeptide; Peptidomimetic drugs	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Cefoxitin	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ybgH	Escherichia coli	Escherichia coli	.	.	.	The protein ybgh of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Dipeptide; Tripeptide; Peptidomimetic drugs	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ydgR	Escherichia coli	Escherichia coli	BL21	.	.	The protein ydgR of Escherichia coli BL21 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Chloramphenicol; Sulpiride	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ydgR	Escherichia coli	Escherichia coli	.	.	.	The protein ydgr of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Dipeptide; Tripeptide; Peptidomimetic drugs	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ydgR	Escherichia coli	Escherichia coli	.	.	.	The protein ydgr of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Sulpiride; Bestatin; Valacyclovir; Ampicillin; Oseltamivir	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	.	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Dipeptide; Tripeptide; Peptidomimetic drugs	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yjdL	Escherichia coli	Escherichia coli	.	.	.	The protein yjdl of Escherichia coli has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	Dipeptide; Tripeptide; Peptidomimetic drugs	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	GK2020	Geobacillus kaustophilus	Geobacillus kaustophilus	.	.	.	The protein gk2020 of Geobacillus kaustophilus has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PepTSh	Staphylococcus hominis	Staphylococcus hominis	SK119	.	.	The protein PepTSh of Staphylococcus hominis SK119 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PepTSo	Shewanella oneidensis	Shewanella oneidensis	.	.	.	The protein peptso of Shewanella oneidensis has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PepTSo2	Shewanella oneidensis	Shewanella oneidensis	.	.	.	The protein peptso2 of Shewanella oneidensis has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PepTSt	Streptococcus thermophilus	Streptococcus thermophilus	LMG 18311	.	.	The protein PepTSt of Streptococcus thermophilus LMG 18311 has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0021	SLC15A1	Co-transporter	.	Co-transport of human SLC15A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YePEPT	Yersinia enterocolitica	Yersinia enterocolitica	.	.	.	The protein yepept of Yersinia enterocolitica has been reported to transport similar substrates/drugs of SLC15A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0021	SLC15A1	Up regulating	Colon cancer	Up regulating of SLC15A1 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco-2)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC15A1.	.	Colon
DTD0021	SLC15A1	Up regulating	Colon cancer	Up regulating of SLC15A1 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco-2)	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC15A1.	.	Colon
DTD0021	SLC15A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC15A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6N mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC15A1.	.	Small intestine
DTD0021	SLC15A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC15A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC15A1.	.	Large intestine
DTD0021	SLC15A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC15A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC15A1.	.	Jejunum
DTD0021	SLC15A1	Down regulating	Hypoxia	Down regulating of SLC15A1 expression in hypoxia condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC15A1.	.	Liver
DTD0022	SLC15A2	Co-transporter	.	Co-transport of human SLC15A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PepTSh	Staphylococcus hominis	Staphylococcus hominis	SK119	.	.	The protein PepTSh of Staphylococcus hominis SK119 has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0022	SLC15A2	Co-transporter	.	Co-transport of human SLC15A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PepTSo	Shewanella oneidensis	Shewanella oneidensis	.	.	.	The protein peptso of Shewanella oneidensis has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0022	SLC15A2	Co-transporter	.	Co-transport of human SLC15A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PepTSo2	Shewanella oneidensis	Shewanella oneidensis	.	.	.	The protein peptso2 of Shewanella oneidensis has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0022	SLC15A2	Co-transporter	.	Co-transport of human SLC15A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PepTSt	Streptococcus thermophilus	Streptococcus thermophilus	LMG 18311	.	.	The protein PepTSt of Streptococcus thermophilus LMG 18311 has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0022	SLC15A2	Co-transporter	.	Co-transport of human SLC15A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ybgH	Escherichia coli	Escherichia coli	BL21	.	.	The protein ybgH of Escherichia coli BL21 has been reported to transport similar substrates/drugs of SLC15A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0100	SLC16A1	Down regulating	Starvation	Down regulating of SLC16A1 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A1.	.	Kidney
DTD0100	SLC16A1	Up regulating	Starvation	Up regulating of SLC16A1 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A1.	.	Small intestine
DTD0100	SLC16A1	Down regulating	Starvation	Down regulating of SLC16A1 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A1.	.	Kidney
DTD0100	SLC16A1	Up regulating	Starvation	Up regulating of SLC16A1 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A1.	.	Small intestine
DTD0100	SLC16A1	Down regulating	Starvation	Down regulating of SLC16A1 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Propionate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A1.	.	Kidney
DTD0100	SLC16A1	Up regulating	Starvation	Up regulating of SLC16A1 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Propionate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A1.	.	Small intestine
DTD0100	SLC16A1	Up regulating	Health	Up regulating of SLC16A1 expression in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Acetate	Pectin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	.	The metabolite acetate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Colon
DTD0100	SLC16A1	Up regulating	Health	Up regulating of SLC16A1 expression in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Acetate	Pectin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	.	The metabolite acetate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Duodenum
DTD0100	SLC16A1	Up regulating	Health	Up regulating of SLC16A1 expression in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Acetate	Pectin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	.	The metabolite acetate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Stomach
DTD0100	SLC16A1	Up regulating	Health	Up regulating of SLC16A1 expression in health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Acetate	Pectin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	.	The metabolite acetate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Caecum
DTD0100	SLC16A1	Up regulating	Colon cancer	Up regulating of SLC16A1 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Dietary food metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco-2)	The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Colonic lumen
DTD0100	SLC16A1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC16A1 expression in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Dietary food metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Landrace-Pietrain hybrid pigs	.	The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Ileum
DTD0100	SLC16A1	Up regulating	Intestinal inflammation	Up regulating of SLC16A1 expression in intestinal inflammation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	beta-glucan metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Landrace-Yorkshire pigs	.	The metabolite butyrate generated from the metabolism of beta-glucan by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Colon
DTD0100	SLC16A1	Up regulating	Intestinal inflammation	Up regulating of SLC16A1 expression in intestinal inflammation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	beta-glucan metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Landrace-Yorkshire pigs	.	The metabolite butyrate generated from the metabolism of beta-glucan by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Caecum
DTD0100	SLC16A1	Up regulating	.	Up regulating of SLC16A1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Rat small intestine epithelial cells (IEC-6)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC16A1.	.	Small intestine
DTD0107	SLC16A3	Up regulating	Starvation	Up regulating of SLC16A3 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.	.	Heart
DTD0107	SLC16A3	Up regulating	Starvation	Up regulating of SLC16A3 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.	.	Small intestine
DTD0107	SLC16A3	Up regulating	Starvation	Up regulating of SLC16A3 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.	.	Heart
DTD0107	SLC16A3	Up regulating	Starvation	Up regulating of SLC16A3 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.	.	Small intestine
DTD0107	SLC16A3	Up regulating	Starvation	Up regulating of SLC16A3 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Propionate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.	.	Heart
DTD0107	SLC16A3	Up regulating	Starvation	Up regulating of SLC16A3 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Propionate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A3.	.	Small intestine
DTD0111	SLC16A7	Down regulating	Starvation	Down regulating of SLC16A7 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A7.	.	Liver
DTD0111	SLC16A7	Up regulating	Starvation	Up regulating of SLC16A7 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.	.	Heart
DTD0111	SLC16A7	Up regulating	Starvation	Up regulating of SLC16A7 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.	.	Hypothalamus
DTD0111	SLC16A7	Up regulating	Starvation	Up regulating of SLC16A7 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.	.	Kidney
DTD0111	SLC16A7	Down regulating	Starvation	Down regulating of SLC16A7 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC16A7.	.	Liver
DTD0111	SLC16A7	Up regulating	Starvation	Up regulating of SLC16A7 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.	.	Heart
DTD0111	SLC16A7	Up regulating	Starvation	Up regulating of SLC16A7 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.	.	Hypothalamus
DTD0111	SLC16A7	Up regulating	Starvation	Up regulating of SLC16A7 expression in starvation condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	129S1/SvImJ mice	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC16A7.	.	Kidney
DTD0123	SLC18A1	Sequestration substrate	.	Sequestration of human SLC18A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Helicobacter pylori	Helicobacter pylori	Helicobacter pylori	ATCC 700824	.	Human gastric epithelial cells	The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC18A1, thereby affecting the efficacy, safety, or bioavailability of the drug.	L-dopamine	Stomach
DTD0034	SLC18A2	Sequestration substrate	.	Sequestration of human SLC18A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Helicobacter pylori	Helicobacter pylori	Helicobacter pylori	ATCC 700824	.	Human gastric epithelial cells	The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC18A2, thereby affecting the efficacy, safety, or bioavailability of the drug.	L-dopamine	Stomach
DTD0132	SLC1A4	Down regulating	Mastitis	Down regulating of SLC1A4 expression in mastitis condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	O111:B4	ICR mice	.	The compound Lipopolysaccharide Generated by Escherichia coli O111:B4 has been reported to decrease the expression of the drug transporter SLC1A4.	.	Breast
DTD0010	SLC22A1	Sequestration substrate	.	Sequestration of human SLC22A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Helicobacter pylori	Helicobacter pylori	Helicobacter pylori	ATCC 700824	.	Human gastric epithelial cells	The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A1, thereby affecting the efficacy, safety, or bioavailability of the drug.	L-dopamine	Stomach
DTD0010	SLC22A1	Co-transporter	.	Co-transport of human SLC22A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	OCT-like transport	Ligilactobacillus salivarius	Ligilactobacillus salivarius	DSM 20555 = ATCC 11741	.	.	The protein OCT-like transport of Ligilactobacillus salivarius DSM 20555 = ATCC 11741 has been reported to transport similar substrates/drugs of SLC22A1, which affects the distribution of its substrate/drug in vivo.	Cationic drugs; Endogenous amines	.
DTD0010	SLC22A1	Up regulating	Diabetes	Up regulating of SLC22A1 expression in diabetes condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Rats	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.	Metformin	Liver
DTD0010	SLC22A1	Up regulating	Colon cancer	Up regulating of SLC22A1 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco-2)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.	.	Colon
DTD0010	SLC22A1	Up regulating	Colon cancer	Up regulating of SLC22A1 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Deoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (HT-29)	The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.	.	Colon
DTD0010	SLC22A1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC22A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.	.	Duodenum
DTD0010	SLC22A1	Up regulating	.	Up regulating of SLC22A1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Lithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	IQI mice	.	The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.	.	Liver
DTD0026	SLC22A11	Sequestration substrate	.	Sequestration of human SLC22A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	str. K-12 substr. MG1655	.	.	The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A11, thereby affecting the efficacy, safety, or bioavailability of the drug.	Tetracycline	.
DTD0026	SLC22A11	Co-transporter	.	Co-transport of human SLC22A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC22A11, which affects the distribution of its substrate/drug in vivo.	Tetracycline	.
DTD0027	SLC22A12	Down regulating	Hyperuricaemia	Down regulating of SLC22A12 expression in hyperuricaemia condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	ICR specific-pathogen-free mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A12.	.	Kidney
DTD0006	SLC22A2	Sequestration substrate	.	Sequestration of human SLC22A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Helicobacter pylori	Helicobacter pylori	Helicobacter pylori	ATCC 700824	.	Human gastric epithelial cells	The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A2, thereby affecting the efficacy, safety, or bioavailability of the drug.	L-dopamine	Stomach
DTD0009	SLC22A3	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC22A3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A3.	.	Liver
DTD0009	SLC22A3	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC22A3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A3.	.	Jejunum
DTD0151	SLC22A4	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC22A4 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A4.	.	Large intestine
DTD0151	SLC22A4	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC22A4 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A4.	.	Liver
DTD0023	SLC22A5	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC22A5 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC22A5.	.	Jejunum
DTD0023	SLC22A5	Inhibition	.	Inhibition of SLC22A5 function in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	N,N,N-trimethyl-5-aminovaleric acid	L-lysine metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite n,n,n-trimethyl-5-aminovaleric acid generated from the metabolism of l-lysine by the host unspecified microbiota has been reported to inhibit the function of the drug transporter SLC22A5.	.	Heart
DTD0024	SLC22A6	Up regulating	Colon cancer	Up regulating of SLC22A6 expression in colon cancer condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli Nissle 1917	Escherichia coli	Escherichia coli	Nissle 1917	.	Human colon adenocarcinoma cells (Caco-2)	The Escherichia coli Nissle 1917 has been reported to increase the expression of the drug transporter SLC22A6.	.	Colon
DTD0024	SLC22A6	Up regulating	Chronic kidney disease	Up regulating of SLC22A6 expression in chronic kidney disease condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Indoxyl sulfate	Indole metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	Human hepatoblastoma cells (HG2L7.5c1)	The metabolite indoxyl sulfate generated from the metabolism of indole by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A6.	.	Kidney
DTD0005	SLC22A7	Sequestration substrate	.	Sequestration of human SLC22A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	str. K-12 substr. MG1655	.	.	The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A7, thereby affecting the efficacy, safety, or bioavailability of the drug.	Tetracycline	.
DTD0005	SLC22A7	Co-transporter	.	Co-transport of human SLC22A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC22A7, which affects the distribution of its substrate/drug in vivo.	Tetracycline	.
DTD0025	SLC22A8	Sequestration substrate	.	Sequestration of human SLC22A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	str. K-12 substr. MG1655	.	.	The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Ciprofloxacin and Tetracycline, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A8, thereby affecting the efficacy, safety, or bioavailability of the drug.	Ciprofloxacin; Tetracycline	.
DTD0025	SLC22A8	Co-transporter	.	Co-transport of human SLC22A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLC22A8, which affects the distribution of its substrate/drug in vivo.	Tetracycline	.
DTD0025	SLC22A8	Up regulating	.	Up regulating of SLC22A8 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Dehydrolithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	PXR mice	Mouse embryo embryonic stem cells (ES-R1)	The metabolite dehydrolithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A8.	.	Liver
DTD0155	SLC22B3	Sequestration substrate	.	Sequestration of human SLC22B3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Helicobacter pylori	Helicobacter pylori	Helicobacter pylori	ATCC 700824	.	Human gastric epithelial cells	The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22B3, thereby affecting the efficacy, safety, or bioavailability of the drug.	L-dopamine	Stomach
DTD0158	SLC23A1	Down regulating	.	Down regulating of SLC23A1 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by the gut microbiota and Gram negative bacteria	Host unspecified microbiota	.	C57BL/6 mice	Human colon adenocarcinoma cells (Caco-2)	The compound lipopolysaccharide generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC23A1.	.	Colon
DTD0159	SLC23A2	Down regulating	.	Down regulating of SLC23A2 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by the gut microbiota and Gram negative bacteria	Host unspecified microbiota	.	C57BL/6 mice	Human colon adenocarcinoma cells (Caco-2)	The compound lipopolysaccharide generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC23A2.	.	Colon
DTD0183	SLC25A22	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC25A22 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC25A22.	.	Jejunum
DTD0189	SLC25A28	Co-transporter	Pneumonic plague	Co-transport of human SLC25A28 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fepD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	psn	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Sit1p	Candida albicans	Candida albicans	CAF2-1	BALB/c mice	.	The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeAB	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Desferriexochelin 772MS	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	str. Erdman	.	.	The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine B	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine E	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine G1	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CaFTR1	Candida albicans	Candida albicans	.	.	.	The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter coli	Campylobacter coli	W13A	.	.	The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	desA1	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeO	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	O157:H7	.	.	The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatA	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatB	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Fbp	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fec	Shigella flexneri	Shigella flexneri	2a	.	.	The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fecA	Escherichia coli	Escherichia coli	UT5600	.	.	The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Klebsiella pneumoniae	Klebsiella pneumoniae	.	.	.	The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuA	Escherichia coli	Escherichia coli	K-12	.	.	The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuB	Escherichia coli	Escherichia coli	DH5[alpha]	.	.	The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuC	Escherichia coli	Escherichia coli	AB2847	.	.	The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCBG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Streptococcus agalactiae	Streptococcus agalactiae	A909	.	.	The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Haemophilus influenzae	Haemophilus influenzae	R2866	.	.	The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD1	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN2564	.	.	The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA1	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA2	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futB	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	GAPDH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	HtsABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IroA	Escherichia coli	Escherichia coli	CFT073	.	.	The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	iroN	Escherichia coli	Escherichia coli	O18:H7	.	.	The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IrtAB	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	BB	.	.	The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	N100	.	.	The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	FA19	.	.	The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0641	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0704	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv1872c	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SfaABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuA	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuB	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuC	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SirABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus RN4220	.	.	The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sitA	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium JF2043	.	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sll1878	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SstABCD	Staphylococcus aureus	Staphylococcus aureus	W	.	.	The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbp1	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K199	.	.	The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	TonB1	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K1040	.	.	The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB3	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 19606	.	.	The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	138	.	.	The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	2	.	.	The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Sequestration substrate	.	Sequestration of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tuf	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A28, which may affects its substrate/drug distribution in the body.	.	.
DTD0189	SLC25A28	Co-transporter	.	Co-transport of human SLC25A28 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM5-2031.11+	.	.	The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC25A28, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	Pneumonic plague	Co-transport of human SLC25A37 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fepD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	psn	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Sit1p	Candida albicans	Candida albicans	CAF2-1	BALB/c mice	.	The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeAB	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Desferriexochelin 772MS	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	str. Erdman	.	.	The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine B	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine E	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine G1	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CaFTR1	Candida albicans	Candida albicans	.	.	.	The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter coli	Campylobacter coli	W13A	.	.	The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	desA1	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeO	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	O157:H7	.	.	The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatA	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatB	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Fbp	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fec	Shigella flexneri	Shigella flexneri	2a	.	.	The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fecA	Escherichia coli	Escherichia coli	UT5600	.	.	The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Klebsiella pneumoniae	Klebsiella pneumoniae	.	.	.	The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuA	Escherichia coli	Escherichia coli	K-12	.	.	The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuB	Escherichia coli	Escherichia coli	DH5[alpha]	.	.	The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuC	Escherichia coli	Escherichia coli	AB2847	.	.	The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCBG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Streptococcus agalactiae	Streptococcus agalactiae	A909	.	.	The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Haemophilus influenzae	Haemophilus influenzae	R2866	.	.	The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD1	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN2564	.	.	The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA1	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA2	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futB	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	GAPDH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	HtsABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IroA	Escherichia coli	Escherichia coli	CFT073	.	.	The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	iroN	Escherichia coli	Escherichia coli	O18:H7	.	.	The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IrtAB	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	BB	.	.	The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	N100	.	.	The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	FA19	.	.	The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0641	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0704	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv1872c	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SfaABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuA	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuB	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuC	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SirABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus RN4220	.	.	The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sitA	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium JF2043	.	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sll1878	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SstABCD	Staphylococcus aureus	Staphylococcus aureus	W	.	.	The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbp1	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K199	.	.	The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	TonB1	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K1040	.	.	The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB3	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 19606	.	.	The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	138	.	.	The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	2	.	.	The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Sequestration substrate	.	Sequestration of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tuf	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC25A37, which may affects its substrate/drug distribution in the body.	.	.
DTD0199	SLC25A37	Co-transporter	.	Co-transport of human SLC25A37 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM5-2031.11+	.	.	The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC25A37, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0231	SLC26A3	Up regulating	Diarrhea	Up regulating of SLC26A3 expression in diarrhea condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus acidophilus	Lactobacillus acidophilus	Lactobacillus acidophilus	ATCC 4357	C57BL/6J mice	Human colon adenocarcinoma cells (Caco-2)	The Lactobacillus acidophilus ATCC 4357 has been reported to increase the expression of the drug transporter SLC26A3.	.	Colon
DTD0231	SLC26A3	Up regulating	Type 2 diabetes mellitus	Up regulating of SLC26A3 expression in type 2 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus casei	Lacticaseibacillus casei	Lacticaseibacillus casei	str. Zhang	Sprague-Dawley rats	.	The Lacticaseibacillus casei str. Zhang has been reported to increase the expression of the drug transporter SLC26A3.	.	Kidney
DTD0231	SLC26A3	Down regulating	Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli	Down regulating of SLC26A3 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	C57BL/6 microflora	Host unspecified microbiota	Host unspecified microbiota	.	FVB/N mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC26A3.	.	Colon
DTD0231	SLC26A3	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC26A3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A3.	.	Colon
DTD0231	SLC26A3	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC26A3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A3.	.	Ileum
DTD0231	SLC26A3	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC26A3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Unspecified Gut microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A3.	.	Ileum/colon
DTD0231	SLC26A3	Up regulating	.	Up regulating of SLC26A3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Dietary food metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Human colon adenocarcinoma cells (LS174T)	The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A3.	.	Colon
DTD0234	SLC26A6	Up regulating	Type 2 diabetes mellitus	Up regulating of SLC26A6 expression in type 2 diabetes mellitus condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus casei	Lacticaseibacillus casei	Lacticaseibacillus casei	str. Zhang	Sprague-Dawley rats	.	The Lacticaseibacillus casei str. Zhang has been reported to increase the expression of the drug transporter SLC26A6.	.	Kidney
DTD0234	SLC26A6	Down regulating	Urinary stone disease	Down regulating of SLC26A6 expression in urinary stone disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6N mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC26A6.	.	Kidney
DTD0234	SLC26A6	Down regulating	Urinary stone disease	Down regulating of SLC26A6 expression in urinary stone disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6N mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC26A6.	.	Colon
DTD0234	SLC26A6	Up regulating	Urinary stone disease	Up regulating of SLC26A6 expression in urinary stone disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6N mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC26A6.	.	Caecum
DTD0238	SLC27A1	Down regulating	Pregnancy	Down regulating of SLC27A1 expression in pregnancy condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bifidobacterium breve UCC2003	Bifidobacterium breve	Bifidobacterium breve	UCC2003	C57BL/6J germ-free mice	.	The Bifidobacterium breve UCC2003 has been reported to decrease the expression of the drug transporter SLC27A1.	.	Placenta
DTD0240	SLC27A3	Down regulating	Mastitis	Down regulating of SLC27A3 expression in mastitis condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	O111:B4	ICR mice	.	The compound Lipopolysaccharide Generated by Escherichia coli O111:B4 has been reported to decrease the expression of the drug transporter SLC27A3.	.	Breast
DTD0241	SLC27A4	Up regulating	Pregnancy	Up regulating of SLC27A4 expression in pregnancy condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bifidobacterium breve UCC2003	Bifidobacterium breve	Bifidobacterium breve	UCC2003	C57BL/6J germ-free mice	.	The Bifidobacterium breve UCC2003 has been reported to increase the expression of the drug transporter SLC27A4.	.	Placenta
DTD0244	SLC28A1	Co-transporter	.	Co-transport of human SLC28A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	nupC	Escherichia coli	Escherichia coli	HB101	.	.	The protein nupC of Escherichia coli HB101 has been reported to transport similar substrates/drugs of SLC28A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0244	SLC28A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC28A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A1.	.	Ileum
DTD0244	SLC28A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC28A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A1.	.	Jejunum
DTD0245	SLC28A2	Co-transporter	.	Co-transport of human SLC28A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	nupC	Escherichia coli	Escherichia coli	HB101	.	.	The protein nupC of Escherichia coli HB101 has been reported to transport similar substrates/drugs of SLC28A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0245	SLC28A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC28A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A2.	.	Ileum
DTD0245	SLC28A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC28A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A2.	.	Large intestine
DTD0245	SLC28A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC28A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC28A2.	.	Duodenum
DTD0246	SLC28A3	Co-transporter	.	Co-transport of human SLC28A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	nupC	Escherichia coli	Escherichia coli	HB101	.	.	The protein nupC of Escherichia coli HB101 has been reported to transport similar substrates/drugs of SLC28A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0247	SLC29A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC29A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J germ-free mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC29A1.	.	Liver
DTD0250	SLC29A4	Co-transporter	.	Co-transport of human SLC29A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PMAT-like transport	Ligilactobacillus salivarius	Ligilactobacillus salivarius	DSM 20555 = ATCC 11741	.	.	The protein PMAT-like transport of Ligilactobacillus salivarius DSM 20555 = ATCC 11741 has been reported to transport similar substrates/drugs of SLC29A4, which affects the distribution of its substrate/drug in vivo.	Cationic drugs; Endogenous amines	.
DTD0250	SLC29A4	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC29A4 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC29A4.	.	Jejunum
DTD0251	SLC2A1	Co-transporter	.	Co-transport of human SLC2A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VIN7_1225	Saccharomyces cerevisiae	Saccharomyces cerevisiae	.	.	.	The protein vin7_1225 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A1, which affects the distribution of its substrate/drug in vivo.	Arsenite	.
DTD0251	SLC2A1	Co-transporter	.	Co-transport of human SLC2A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VIN7_3230	Saccharomyces cerevisiae	Saccharomyces cerevisiae	.	.	.	The protein vin7_3230 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A1, which affects the distribution of its substrate/drug in vivo.	Arsenite	.
DTD0251	SLC2A1	Co-transporter	.	Co-transport of human SLC2A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VIN7_5215	Saccharomyces cerevisiae	Saccharomyces cerevisiae	.	.	.	The protein vin7_5215 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A1, which affects the distribution of its substrate/drug in vivo.	Arsenite	.
DTD0251	SLC2A1	Down regulating	Mastitis	Down regulating of SLC2A1 expression in mastitis condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	O111:B4	ICR mice	.	The compound Lipopolysaccharide Generated by Escherichia coli O111:B4 has been reported to decrease the expression of the drug transporter SLC2A1.	.	Breast
DTD0251	SLC2A1	Up regulating	Pregnancy	Up regulating of SLC2A1 expression in pregnancy condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bifidobacterium breve UCC2003	Bifidobacterium breve	Bifidobacterium breve	UCC2003	C57BL/6J germ-free mice	.	The Bifidobacterium breve UCC2003 has been reported to increase the expression of the drug transporter SLC2A1.	.	Placenta
DTD0257	SLC2A2	Down regulating	Gastrointestinal disturbances in children with autism	Down regulating of SLC2A2 expression in gastrointestinal disturbances expression in children with autism condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bacteroides Vulgatus isolates(down)	Bacteroides Vulgatus	Bacteroides Vulgatus	.	Children with autistic disorder and GI disease	.	The Bacteroides Vulgatus has been reported to decrease the expression of the drug transporter SLC2A2.	.	Ileum
DTD0257	SLC2A2	Down regulating	Gastrointestinal disturbances in children with autism	Down regulating of SLC2A2 expression in gastrointestinal disturbances expression in children with autism condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Faecalibacterium prausnitzii isolates	Faecalibacterium prausnitzii	Faecalibacterium prausnitzii	.	Children with autistic disorder and GI disease	.	The Faecalibacterium prausnitzii has been reported to decrease the expression of the drug transporter SLC2A2.	.	Ileum
DTD0257	SLC2A2	Up regulating	.	Up regulating of SLC2A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	Sprague-Dawley rats	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC2A2.	.	Ileum
DTD0257	SLC2A2	Up regulating	.	Up regulating of SLC2A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	Sprague-Dawley rats	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC2A2.	.	Ileum
DTD0257	SLC2A2	Up regulating	.	Up regulating of SLC2A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Propionate)	Dietary food metabolite from Prevotella copri	Prevotella copri	.	Sprague-Dawley rats	.	The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary food by the Prevotella copri has been reported to increase the expression of the drug transporter SLC2A2.	.	Ileum
DTD0257	SLC2A2	Up regulating	Colon cancer	Up regulating of SLC2A2 expression in colon cancer condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Dietary food metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Human colon adenocarcinoma cells (Caco2-BBE)	The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.	.	Colon
DTD0257	SLC2A2	Up regulating	.	Up regulating of SLC2A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	7-Sulfocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite 7-sulfocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.	.	Liver
DTD0257	SLC2A2	Up regulating	.	Up regulating of SLC2A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Muricholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite muricholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.	.	Liver
DTD0257	SLC2A2	Up regulating	.	Up regulating of SLC2A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Taurocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite taurocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.	.	Liver
DTD0257	SLC2A2	Up regulating	.	Up regulating of SLC2A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Taurodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite taurodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A2.	.	Liver
DTD0262	SLC2A4	Co-transporter	.	Co-transport of human SLC2A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VIN7_1225	Saccharomyces cerevisiae	Saccharomyces cerevisiae	.	.	.	The protein vin7_1225 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A4, which affects the distribution of its substrate/drug in vivo.	Arsenite	.
DTD0262	SLC2A4	Co-transporter	.	Co-transport of human SLC2A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VIN7_3230	Saccharomyces cerevisiae	Saccharomyces cerevisiae	.	.	.	The protein vin7_3230 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A4, which affects the distribution of its substrate/drug in vivo.	Arsenite	.
DTD0262	SLC2A4	Co-transporter	.	Co-transport of human SLC2A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	VIN7_5215	Saccharomyces cerevisiae	Saccharomyces cerevisiae	.	.	.	The protein vin7_5215 of Saccharomyces cerevisiae has been reported to transport similar substrates/drugs of SLC2A4, which affects the distribution of its substrate/drug in vivo.	Arsenite	.
DTD0262	SLC2A4	Up regulating	.	Up regulating of SLC2A4 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	Mouse white adipose tissue preadipocytes cells (3T3-L1)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC2A4.	.	Liver
DTD0267	SLC2A9	Down regulating	Hyperuricaemia	Down regulating of SLC2A9 expression in hyperuricaemia condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	ICR specific-pathogen-free mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC2A9.	.	Kidney
DTD0269	SLC30A1	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A1 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0269	SLC30A1	Co-transporter	Health	Co-transport of human SLC30A1 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0269	SLC30A1	Co-transporter	.	Co-transport of human SLC30A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctpC	Mycobacterium tuberculosis	Mycobacterium tuberculosis	GC1237	.	.	The protein ctpC of Mycobacterium tuberculosis GC1237 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0269	SLC30A1	Co-transporter	.	Co-transport of human SLC30A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctpG	Mycobacterium tuberculosis	Mycobacterium tuberculosis	GC1237	.	.	The protein ctpG of Mycobacterium tuberculosis GC1237 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0269	SLC30A1	Co-transporter	.	Co-transport of human SLC30A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0269	SLC30A1	Co-transporter	.	Co-transport of human SLC30A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0269	SLC30A1	Co-transporter	.	Co-transport of human SLC30A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0269	SLC30A1	Co-transporter	.	Co-transport of human SLC30A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0269	SLC30A1	Up regulating	.	Up regulating of SLC30A1 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by the gut microbiota and Gram negative bacteria	Host unspecified microbiota	.	C57BL/6 mice	.	The compound lipopolysaccharide generated by host unspecified microbiota has been reported to increase the expression of the drug transporter SLC30A1.	.	Spleen
DTD0270	SLC30A10	Sequestration substrate	Upper and lower airway disease	Sequestration of human SLC30A10 substrates/drugs in upper and lower airway disease condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. equi NCTC 9682	Swiss Webster mice	.	The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0270	SLC30A10	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A10 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0270	SLC30A10	Sequestration substrate	Sepsis	Sequestration of human SLC30A10 substrates/drugs in sepsis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Streptococcus suis	Streptococcus suis	serotype 9	CD-1 mice	.	The protein troA of Streptococcus suis serotype 9 has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.	.	Liver
DTD0270	SLC30A10	Co-transporter	Health	Co-transport of human SLC30A10 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0270	SLC30A10	Co-transporter	.	Co-transport of human SLC30A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0270	SLC30A10	Co-transporter	.	Co-transport of human SLC30A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mnoP	Bradyrhizobium diazoefficiens	Bradyrhizobium diazoefficiens	USDA 110	.	.	The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0270	SLC30A10	Sequestration substrate	.	Sequestration of human SLC30A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. zooepidemicus NCTC 7023T	.	.	The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.	.	.
DTD0270	SLC30A10	Sequestration substrate	.	Sequestration of human SLC30A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.	.	.
DTD0270	SLC30A10	Sequestration substrate	.	Sequestration of human SLC30A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tssS	Yersinia pseudotuberculosis	Yersinia pseudotuberculosis	YPIII	.	.	The protein tssS of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC30A10, which may affects its substrate/drug distribution in the body.	.	.
DTD0270	SLC30A10	Co-transporter	.	Co-transport of human SLC30A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0270	SLC30A10	Co-transporter	.	Co-transport of human SLC30A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0270	SLC30A10	Co-transporter	.	Co-transport of human SLC30A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0271	SLC30A2	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A2 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0271	SLC30A2	Co-transporter	Health	Co-transport of human SLC30A2 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0271	SLC30A2	Co-transporter	.	Co-transport of human SLC30A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0271	SLC30A2	Co-transporter	.	Co-transport of human SLC30A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0271	SLC30A2	Co-transporter	.	Co-transport of human SLC30A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0271	SLC30A2	Co-transporter	.	Co-transport of human SLC30A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0272	SLC30A3	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A3 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0272	SLC30A3	Co-transporter	Health	Co-transport of human SLC30A3 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0272	SLC30A3	Co-transporter	.	Co-transport of human SLC30A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0272	SLC30A3	Co-transporter	.	Co-transport of human SLC30A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0272	SLC30A3	Co-transporter	.	Co-transport of human SLC30A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0272	SLC30A3	Co-transporter	.	Co-transport of human SLC30A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0273	SLC30A4	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A4 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0273	SLC30A4	Co-transporter	Health	Co-transport of human SLC30A4 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0273	SLC30A4	Co-transporter	.	Co-transport of human SLC30A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0273	SLC30A4	Co-transporter	.	Co-transport of human SLC30A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0273	SLC30A4	Co-transporter	.	Co-transport of human SLC30A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0273	SLC30A4	Co-transporter	.	Co-transport of human SLC30A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0273	SLC30A4	Up regulating	.	Up regulating of SLC30A4 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by the gut microbiota and Gram negative bacteria	Host unspecified microbiota	.	C57BL/6 mice	.	The compound lipopolysaccharide generated by host unspecified microbiota has been reported to increase the expression of the drug transporter SLC30A4.	.	Spleen
DTD0274	SLC30A5	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A5 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0274	SLC30A5	Co-transporter	Health	Co-transport of human SLC30A5 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0274	SLC30A5	Up regulating	.	Up regulating of SLC30A5 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	O55	CD-1 mice	.	The compound Lipopolysaccharide Generated by Escherichia coli O55 has been reported to increase the expression of the drug transporter SLC30A5.	.	Liver
DTD0274	SLC30A5	Co-transporter	.	Co-transport of human SLC30A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0274	SLC30A5	Co-transporter	.	Co-transport of human SLC30A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0274	SLC30A5	Co-transporter	.	Co-transport of human SLC30A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0274	SLC30A5	Co-transporter	.	Co-transport of human SLC30A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0275	SLC30A6	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A6 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0275	SLC30A6	Co-transporter	Health	Co-transport of human SLC30A6 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0275	SLC30A6	Co-transporter	.	Co-transport of human SLC30A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0275	SLC30A6	Co-transporter	.	Co-transport of human SLC30A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0275	SLC30A6	Co-transporter	.	Co-transport of human SLC30A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0275	SLC30A6	Co-transporter	.	Co-transport of human SLC30A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0275	SLC30A6	Up regulating	.	Up regulating of SLC30A6 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by the gut microbiota and Gram negative bacteria	Host unspecified microbiota	.	C57BL/6 mice	.	The compound lipopolysaccharide generated by host unspecified microbiota has been reported to increase the expression of the drug transporter SLC30A6.	.	Spleen
DTD0276	SLC30A7	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A7 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0276	SLC30A7	Co-transporter	Health	Co-transport of human SLC30A7 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0276	SLC30A7	Co-transporter	.	Co-transport of human SLC30A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0276	SLC30A7	Co-transporter	.	Co-transport of human SLC30A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0276	SLC30A7	Co-transporter	.	Co-transport of human SLC30A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0276	SLC30A7	Co-transporter	.	Co-transport of human SLC30A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0035	SLC30A8	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A8 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0035	SLC30A8	Co-transporter	Health	Co-transport of human SLC30A8 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0035	SLC30A8	Co-transporter	.	Co-transport of human SLC30A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0035	SLC30A8	Co-transporter	.	Co-transport of human SLC30A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0035	SLC30A8	Co-transporter	.	Co-transport of human SLC30A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0035	SLC30A8	Co-transporter	.	Co-transport of human SLC30A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0277	SLC30A9	Co-transporter	Acute monocytic leukemia	Co-transport of human SLC30A9 substrates/drugs in acute monocytic leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SPI-1	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. SL1344	.	Human childhood acute monocytic leukemia cells (THP-1)	The protein SPI-1 of Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0277	SLC30A9	Co-transporter	Health	Co-transport of human SLC30A9 substrates/drugs in health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yhiP	Escherichia coli	Escherichia coli	.	.	Human kidney human embryonic kidney 293T cells (HEK 293T)	The protein yhip of Escherichia coli has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.	.	Kidney
DTD0277	SLC30A9	Co-transporter	.	Co-transport of human SLC30A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	czcD	Streptococcus pyogenes	Streptococcus pyogenes	M1T1 5448	.	.	The protein czcD of Streptococcus pyogenes M1T1 5448 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0277	SLC30A9	Co-transporter	.	Co-transport of human SLC30A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	.	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0277	SLC30A9	Co-transporter	.	Co-transport of human SLC30A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The protein zupT of Escherichia coli str. K-12 substr. W3110 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0277	SLC30A9	Co-transporter	.	Co-transport of human SLC30A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Escherichia coli	Escherichia coli	GR352	.	.	The protein zupT of Escherichia coli GR352 has been reported to transport similar substrates/drugs of SLC30A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Sequestration substrate	Leukemia	Sequestration of human SLC31A1 substrates/drugs in leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Methanobactin	Secreted by Yersinia pestis	Yersinia pestis	.	.	Mouse leukemia cells (RAW 264.7)	The compound methanobactin secreted by Yersinia pestis has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0278	SLC31A1	Sequestration substrate	.	Sequestration of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Methanobactin	Secreted by Methylosinus trichosporium	Methylosinus trichosporium	OB3b	.	.	The compound Methanobactin Secreted by Methylosinus trichosporium OB3b has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0278	SLC31A1	Sequestration substrate	.	Sequestration of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphylopine	Secreted by Staphylococcus aureus	Staphylococcus aureus	.	.	.	The compound staphylopine secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ccoA	Cereibacter sphaeroides	Cereibacter sphaeroides	Ga	.	.	The protein ccoA of Cereibacter sphaeroides Ga has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ccoA	Rhodobacter capsulatus	Rhodobacter capsulatus	MT1131	.	.	The protein ccoA of Rhodobacter capsulatus MT1131 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Helicobacter pylori	Helicobacter pylori	11637	.	.	The protein feob of Helicobacter pylori 11637 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Escherichia coli	Escherichia coli	UTI89	.	.	The protein fyuA of Escherichia coli UTI89 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein mntH of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mspA	Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	SMR5	.	.	The protein mspA of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mspB	Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	SMR5	.	.	The protein mspB of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mspC	Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	SMR5	.	.	The protein mspC of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mspD	Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	SMR5	.	.	The protein mspD of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Sequestration substrate	.	Sequestration of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mymT	Mycobacterium tuberculosis	Mycobacterium tuberculosis	.	.	.	The protein mymt of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	K-12	.	.	The protein ompF of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	oprC	Stutzerimonas stutzeri	Stutzerimonas stutzeri	JM300	.	.	The protein oprC of Stutzerimonas stutzeri JM300 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	oprC	Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The protein oprC of Pseudomonas aeruginosa PAO1 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0278	SLC31A1	Sequestration substrate	.	Sequestration of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0278	SLC31A1	Sequestration substrate	.	Sequestration of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	smtA	Synechococcus elongatus	Synechococcus elongatus	PCC 7942	.	.	The protein smtA of Synechococcus elongatus PCC 7942 has been reported to sequester the substrate/drug of SLC31A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0278	SLC31A1	Co-transporter	.	Co-transport of human SLC31A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ybtPQ	Escherichia coli	Escherichia coli	UTI89	.	.	The protein ybtPQ of Escherichia coli UTI89 has been reported to transport similar substrates/drugs of SLC31A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Sequestration substrate	Leukemia	Sequestration of human SLC31A2 substrates/drugs in leukemia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Methanobactin	Secreted by Yersinia pestis	Yersinia pestis	.	.	Mouse leukemia cells (RAW 264.7)	The compound methanobactin secreted by Yersinia pestis has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0280	SLC31A2	Sequestration substrate	.	Sequestration of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Methanobactin	Secreted by Methylosinus trichosporium	Methylosinus trichosporium	OB3b	.	.	The compound Methanobactin Secreted by Methylosinus trichosporium OB3b has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0280	SLC31A2	Sequestration substrate	.	Sequestration of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphylopine	Secreted by Staphylococcus aureus	Staphylococcus aureus	.	.	.	The compound staphylopine secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ccoA	Cereibacter sphaeroides	Cereibacter sphaeroides	Ga	.	.	The protein ccoA of Cereibacter sphaeroides Ga has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ccoA	Rhodobacter capsulatus	Rhodobacter capsulatus	MT1131	.	.	The protein ccoA of Rhodobacter capsulatus MT1131 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Helicobacter pylori	Helicobacter pylori	11637	.	.	The protein feob of Helicobacter pylori 11637 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Escherichia coli	Escherichia coli	UTI89	.	.	The protein fyuA of Escherichia coli UTI89 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mntH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein mntH of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mspA	Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	SMR5	.	.	The protein mspA of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mspB	Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	SMR5	.	.	The protein mspB of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mspC	Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	SMR5	.	.	The protein mspC of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mspD	Mycolicibacterium smegmatis	Mycolicibacterium smegmatis	SMR5	.	.	The protein mspD of Mycolicibacterium smegmatis SMR5 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Sequestration substrate	.	Sequestration of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mymT	Mycobacterium tuberculosis	Mycobacterium tuberculosis	.	.	.	The protein mymt of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	K-12	.	.	The protein ompF of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	oprC	Stutzerimonas stutzeri	Stutzerimonas stutzeri	JM300	.	.	The protein oprC of Stutzerimonas stutzeri JM300 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	oprC	Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The protein oprC of Pseudomonas aeruginosa PAO1 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0280	SLC31A2	Sequestration substrate	.	Sequestration of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0280	SLC31A2	Sequestration substrate	.	Sequestration of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	smtA	Synechococcus elongatus	Synechococcus elongatus	PCC 7942	.	.	The protein smtA of Synechococcus elongatus PCC 7942 has been reported to sequester the substrate/drug of SLC31A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0280	SLC31A2	Co-transporter	.	Co-transport of human SLC31A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ybtPQ	Escherichia coli	Escherichia coli	UTI89	.	.	The protein ybtPQ of Escherichia coli UTI89 has been reported to transport similar substrates/drugs of SLC31A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0298	SLC35D1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC35D1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC35D1.	.	Colon
DTD0318	SLC36A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC36A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC36A1.	.	Jejunum
DTD0330	SLC38A3	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC38A3 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC38A3.	.	Brown adipose tissue
DTD0337	SLC39A1	Sequestration substrate	Septicemic plague	Sequestration of human SLC39A1 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The compound Yersiniabactin Secreted by Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0337	SLC39A1	Sequestration substrate	Colon cancer	Sequestration of human SLC39A1 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0337	SLC39A1	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A1 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0337	SLC39A1	Co-transporter	Cholera	Co-transport of human SLC39A1 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0337	SLC39A1	Co-transporter	Septicemic plague	Co-transport of human SLC39A1 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0337	SLC39A1	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A1 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0337	SLC39A1	Co-transporter	Cholera	Co-transport of human SLC39A1 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ybtX	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	Mouse leukemia cells (RAW 274.6)	The protein ybtX of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yezP	Yersinia pseudotuberculosis	Yersinia pseudotuberculosis	YPIII	C57BL/6 mice	.	The protein yezP of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zupT	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein zupT of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphylopine	Secreted by Staphylococcus aureus	Staphylococcus aureus	.	.	.	The compound staphylopine secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	bmtA	Borreliella burgdorferi	Borreliella burgdorferi	297	.	.	The protein bmta of Borreliella burgdorferi 297 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PRA1	Candida albicans	Candida albicans	M134	.	.	The protein PRA1 of Candida albicans M134 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	PZP1	Haemophilus influenzae	Haemophilus influenzae	NTHI6564	.	.	The protein PZP1 of Haemophilus influenzae NTHI6564 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbp1	Neisseria meningitidis	Neisseria meningitidis	HB-1	.	.	The protein tbp1 of Neisseria meningitidis HB-1 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	FA19	.	.	The protein tbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tdfH	Neisseria gonorrhoeae	Neisseria gonorrhoeae	FA19	.	.	The protein tdfH of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	.	.	.	The protein troa of Treponema pallidum has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Sequestration substrate	.	Sequestration of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0337	SLC39A1	Co-transporter	.	Co-transport of human SLC39A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Sequestration substrate	Colon cancer	Sequestration of human SLC39A10 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0338	SLC39A10	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A10 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0338	SLC39A10	Co-transporter	Cholera	Co-transport of human SLC39A10 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0338	SLC39A10	Co-transporter	Septicemic plague	Co-transport of human SLC39A10 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0338	SLC39A10	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A10 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0338	SLC39A10	Co-transporter	Cholera	Co-transport of human SLC39A10 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0338	SLC39A10	Down regulating	.	Down regulating of SLC39A10 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	Top10	.	Human peripheral blood cells	The compound Lipopolysaccharide Generated by Escherichia coli Top10 has been reported to decrease the expression of the drug transporter SLC39A10.	.	Blood
DTD0338	SLC39A10	Sequestration substrate	.	Sequestration of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0338	SLC39A10	Sequestration substrate	.	Sequestration of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Sequestration substrate	.	Sequestration of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	.
DTD0338	SLC39A10	Sequestration substrate	.	Sequestration of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	.
DTD0338	SLC39A10	Sequestration substrate	.	Sequestration of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Sequestration substrate	.	Sequestration of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A10, which may affects its substrate/drug distribution in the body.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Co-transporter	.	Co-transport of human SLC39A10 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A10, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0338	SLC39A10	Down regulating	.	Down regulating of SLC39A10 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by the gut microbiota and Gram negative bacteria	Host unspecified microbiota	.	C57BL/6 mice	.	The compound lipopolysaccharide generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC39A10.	.	Spleen
DTD0339	SLC39A11	Sequestration substrate	Colon cancer	Sequestration of human SLC39A11 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0339	SLC39A11	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A11 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0339	SLC39A11	Co-transporter	Cholera	Co-transport of human SLC39A11 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0339	SLC39A11	Co-transporter	Septicemic plague	Co-transport of human SLC39A11 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0339	SLC39A11	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A11 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0339	SLC39A11	Co-transporter	Cholera	Co-transport of human SLC39A11 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0339	SLC39A11	Sequestration substrate	.	Sequestration of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0339	SLC39A11	Sequestration substrate	.	Sequestration of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Sequestration substrate	.	Sequestration of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	.
DTD0339	SLC39A11	Sequestration substrate	.	Sequestration of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	.
DTD0339	SLC39A11	Sequestration substrate	.	Sequestration of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Sequestration substrate	.	Sequestration of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A11, which may affects its substrate/drug distribution in the body.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0339	SLC39A11	Co-transporter	.	Co-transport of human SLC39A11 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A11, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Sequestration substrate	Colon cancer	Sequestration of human SLC39A12 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0340	SLC39A12	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A12 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0340	SLC39A12	Co-transporter	Cholera	Co-transport of human SLC39A12 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0340	SLC39A12	Co-transporter	Septicemic plague	Co-transport of human SLC39A12 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0340	SLC39A12	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A12 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0340	SLC39A12	Co-transporter	Cholera	Co-transport of human SLC39A12 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0340	SLC39A12	Sequestration substrate	.	Sequestration of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0340	SLC39A12	Sequestration substrate	.	Sequestration of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Sequestration substrate	.	Sequestration of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	.
DTD0340	SLC39A12	Sequestration substrate	.	Sequestration of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	.
DTD0340	SLC39A12	Sequestration substrate	.	Sequestration of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Sequestration substrate	.	Sequestration of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A12, which may affects its substrate/drug distribution in the body.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0340	SLC39A12	Co-transporter	.	Co-transport of human SLC39A12 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A12, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Sequestration substrate	Colon cancer	Sequestration of human SLC39A13 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0341	SLC39A13	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A13 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0341	SLC39A13	Co-transporter	Cholera	Co-transport of human SLC39A13 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0341	SLC39A13	Co-transporter	Septicemic plague	Co-transport of human SLC39A13 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0341	SLC39A13	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A13 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0341	SLC39A13	Co-transporter	Cholera	Co-transport of human SLC39A13 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0341	SLC39A13	Sequestration substrate	.	Sequestration of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0341	SLC39A13	Sequestration substrate	.	Sequestration of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Sequestration substrate	.	Sequestration of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	.
DTD0341	SLC39A13	Sequestration substrate	.	Sequestration of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	.
DTD0341	SLC39A13	Sequestration substrate	.	Sequestration of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Sequestration substrate	.	Sequestration of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A13, which may affects its substrate/drug distribution in the body.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0341	SLC39A13	Co-transporter	.	Co-transport of human SLC39A13 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A13, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	Cystic fibrosis	Sequestration of human SLC39A14 substrates/drugs in cystic fibrosis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyochelin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	ATCC 15692	CD-1 mice	.	The compound Pyochelin Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Sequestration substrate	Cystic fibrosis	Sequestration of human SLC39A14 substrates/drugs in cystic fibrosis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyoverdine F-Iib	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	ATCC 15692	CD-1 mice	.	The compound Pyoverdine F-Iib Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Sequestration substrate	Lung adenocarcinoma	Sequestration of human SLC39A14 substrates/drugs in lung adenocarcinoma condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KP20	.	Human lung adenocarcinoma cells (A549)	The compound Salmochelin SX Secreted by Klebsiella pneumoniae KP20 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Sequestration substrate	Pneumonia	Sequestration of human SLC39A14 substrates/drugs in pneumonia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	ATCC 43816	C57BL/6 mice	.	The compound Yersiniabactin Secreted by Klebsiella pneumoniae ATCC 43816 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Co-transporter	Pneumonic plague	Co-transport of human SLC39A14 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0342	SLC39A14	Sequestration substrate	Upper and lower airway disease	Sequestration of human SLC39A14 substrates/drugs in upper and lower airway disease condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. equi NCTC 9682	Swiss Webster mice	.	The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Sequestration substrate	Sepsis	Sequestration of human SLC39A14 substrates/drugs in sepsis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Streptococcus suis	Streptococcus suis	serotype 9	CD-1 mice	.	The protein troA of Streptococcus suis serotype 9 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Liver
DTD0342	SLC39A14	Sequestration substrate	Colon cancer	Sequestration of human SLC39A14 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0342	SLC39A14	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A14 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0342	SLC39A14	Co-transporter	Cholera	Co-transport of human SLC39A14 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0342	SLC39A14	Co-transporter	Septicemic plague	Co-transport of human SLC39A14 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0342	SLC39A14	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A14 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0342	SLC39A14	Co-transporter	Cholera	Co-transport of human SLC39A14 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Intestine
DTD0342	SLC39A14	Up regulating	.	Up regulating of SLC39A14 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	O55	CD-1 mice	.	The compound Lipopolysaccharide Generated by Escherichia coli O55 has been reported to increase the expression of the drug transporter SLC39A14.	.	Liver
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Intestine
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KPPR1	C57BL/6 mice	.	The compound Salmochelin SX Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KPPR1	C57BL/6 mice	.	The compound Yersiniabactin Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fepD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	irp2	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein irp2 of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	psn	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Sit1p	Candida albicans	Candida albicans	CAF2-1	BALB/c mice	.	The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeAB	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 2-oxoadipic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 2-oxoadipic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 2-oxoadipic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 2-oxoadipic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 2-Oxoadipic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 2-Oxoadipic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 2-Oxoadipic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Aerobactin	Secreted by Escherichia coli	Escherichia coli	LG1315	.	.	The compound Aerobactin Secreted by Escherichia coli LG1315 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Achromobacter xylosoxidans	Achromobacter xylosoxidans	subsp. xylosoxydans KN 3-1	.	.	The compound Alcaligin Secreted by Achromobacter xylosoxidans subsp. xylosoxydans KN 3-1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Bordetella bronchiseptica	Bordetella bronchiseptica	B013N	.	.	The compound Alcaligin Secreted by Bordetella bronchiseptica B013N has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Bordetella pertussis	Bordetella pertussis	UT25	.	.	The compound Alcaligin Secreted by Bordetella pertussis UT25 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Anguibactin	Secreted by Vibrio anguillarum	Vibrio anguillarum	775	.	.	The compound anguibactin secreted by Vibrio anguillarum 775 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Aureochelin	Secreted by Staphylococcus aureus	Staphylococcus aureus	.	.	.	The compound aureochelin secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Carboxymycobactin	Secreted by Mycobacterium avium	Mycobacterium avium	CRl/69	.	.	The compound Carboxymycobactin Secreted by Mycobacterium avium CRl/69 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Cepabactin	Secreted by Burkholderia cepacia	Burkholderia cepacia	ATCC 25416	.	.	The compound Cepabactin Secreted by Burkholderia cepacia ATCC 25416 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Corynebacterium diphtheriae	Corynebacterium diphtheriae	C7 (beta)	.	.	The compound Corynebactin Secreted by Corynebacterium diphtheriae C7 (beta) has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The compound Corynebactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus thuringiensis	Bacillus thuringiensis	ATCC 33679	.	.	The compound Corynebactin Secreted by Bacillus thuringiensis ATCC 33679 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The compound Corynebactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Desferriexochelin 772MS	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	str. Erdman	.	.	The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	BW25113	.	.	The compound Enterobactin Secreted by Escherichia coli BW25113 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The compound Enterobactin Secreted by Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. LT2	.	.	The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	298/53	.	.	The compound Enterobactin Secreted by Klebsiella pneumoniae 298/53 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Shigella sonnei	Shigella sonnei	43-GG9	.	.	The compound Enterobactin Secreted by Shigella sonnei 43-GG9 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	9.0111	.	.	The compound enterobactin secreted by Escherichia coli 9.0111 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	AB33II	.	.	The compound Enterobactin Secreted by Escherichia coli AB33II has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Exochelin 772SM	Secreted by Mycolicibacterium vaccae	Mycolicibacterium vaccae	R877R	.	.	The compound Exochelin 772SM Secreted by Mycolicibacterium vaccae R877R has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine B	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine E	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine G1	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound indole-3-pyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound indole-3-pyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound indole-3-pyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound indole-3-pyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound Indole-3-pyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound Indole-3-pyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound Indole-3-pyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ornibactin	Secreted by Burkholderia cepacia	Burkholderia cepacia	TVV69	.	.	The compound Ornibactin Secreted by Burkholderia cepacia TVV69 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Petrobactin	Secreted by Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The compound Petrobactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Petrobactin	Secreted by Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The compound Petrobactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound phenylpyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound phenylpyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound phenylpyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound phenylpyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound Phenylpyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound Phenylpyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound Phenylpyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyochelin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The compound Pyochelin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyoverdin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The compound Pyoverdin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Rhizoferrin	Secreted by Rhizopus microsporus	Rhizopus microsporus	.	.	.	The compound rhizoferrin secreted by Rhizopus microsporus has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salicylic acid	Secreted by Burkholderia cepacia	Burkholderia cepacia	Pc275c	.	.	The compound Salicylic acid Secreted by Burkholderia cepacia Pc275c has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. LT2	.	.	The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphyloferrin A	Secreted by Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The compound Staphyloferrin A Secreted by Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphylopine	Secreted by Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The compound Staphylopine Secreted by Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Vibriobactin	Secreted by Vibrio cholerae	Vibrio cholerae	Lou15	.	.	The compound Vibriobactin Secreted by Vibrio cholerae Lou15 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Vibriobactin	Secreted by Vibrio cholerae	Vibrio cholerae	MBG14	.	.	The compound Vibriobactin Secreted by Vibrio cholerae MBG14 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia pestis	Yersinia pestis	Yreka F1+VW+P1+P+	.	.	The compound Yersiniabactin Secreted by Yersinia pestis Yreka F1+VW+P1+P+ has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The compound Yersiniabactin Secreted by Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CaFTR1	Candida albicans	Candida albicans	.	.	.	The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter coli	Campylobacter coli	W13A	.	.	The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	desA1	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeO	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	O157:H7	.	.	The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatA	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatB	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Fbp	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fec	Shigella flexneri	Shigella flexneri	2a	.	.	The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fecA	Escherichia coli	Escherichia coli	UT5600	.	.	The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Klebsiella pneumoniae	Klebsiella pneumoniae	.	.	.	The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuA	Escherichia coli	Escherichia coli	K-12	.	.	The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuB	Escherichia coli	Escherichia coli	DH5[alpha]	.	.	The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuC	Escherichia coli	Escherichia coli	AB2847	.	.	The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCBG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Streptococcus agalactiae	Streptococcus agalactiae	A909	.	.	The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Haemophilus influenzae	Haemophilus influenzae	R2866	.	.	The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD1	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN2564	.	.	The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA1	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA2	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futB	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	GAPDH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	HtsABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IroA	Escherichia coli	Escherichia coli	CFT073	.	.	The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	iroN	Escherichia coli	Escherichia coli	O18:H7	.	.	The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IrtAB	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	BB	.	.	The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	N100	.	.	The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	FA19	.	.	The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mnoP	Bradyrhizobium diazoefficiens	Bradyrhizobium diazoefficiens	USDA 110	.	.	The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. zooepidemicus NCTC 7023T	.	.	The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0641	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0704	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv1872c	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SfaABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuA	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuB	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuC	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SirABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus RN4220	.	.	The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sitA	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium JF2043	.	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sll1878	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SstABCD	Staphylococcus aureus	Staphylococcus aureus	W	.	.	The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbp1	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K199	.	.	The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	TonB1	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K1040	.	.	The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB3	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 19606	.	.	The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	138	.	.	The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	2	.	.	The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tssS	Yersinia pseudotuberculosis	Yersinia pseudotuberculosis	YPIII	.	.	The protein tssS of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tuf	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM5-2031.11+	.	.	The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Sequestration substrate	.	Sequestration of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A14, which may affects its substrate/drug distribution in the body.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0342	SLC39A14	Co-transporter	.	Co-transport of human SLC39A14 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A14, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Sequestration substrate	Colon cancer	Sequestration of human SLC39A2 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0343	SLC39A2	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A2 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0343	SLC39A2	Co-transporter	Cholera	Co-transport of human SLC39A2 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0343	SLC39A2	Co-transporter	Septicemic plague	Co-transport of human SLC39A2 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0343	SLC39A2	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A2 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0343	SLC39A2	Co-transporter	Cholera	Co-transport of human SLC39A2 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0343	SLC39A2	Sequestration substrate	.	Sequestration of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0343	SLC39A2	Sequestration substrate	.	Sequestration of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Sequestration substrate	.	Sequestration of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0343	SLC39A2	Sequestration substrate	.	Sequestration of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0343	SLC39A2	Sequestration substrate	.	Sequestration of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Sequestration substrate	.	Sequestration of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0343	SLC39A2	Co-transporter	.	Co-transport of human SLC39A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Sequestration substrate	Colon cancer	Sequestration of human SLC39A3 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0344	SLC39A3	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A3 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0344	SLC39A3	Co-transporter	Cholera	Co-transport of human SLC39A3 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0344	SLC39A3	Co-transporter	Septicemic plague	Co-transport of human SLC39A3 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0344	SLC39A3	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A3 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0344	SLC39A3	Co-transporter	Cholera	Co-transport of human SLC39A3 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0344	SLC39A3	Sequestration substrate	.	Sequestration of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0344	SLC39A3	Sequestration substrate	.	Sequestration of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Sequestration substrate	.	Sequestration of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	.
DTD0344	SLC39A3	Sequestration substrate	.	Sequestration of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	.
DTD0344	SLC39A3	Sequestration substrate	.	Sequestration of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Sequestration substrate	.	Sequestration of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A3, which may affects its substrate/drug distribution in the body.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0344	SLC39A3	Co-transporter	.	Co-transport of human SLC39A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Sequestration substrate	Colon cancer	Sequestration of human SLC39A4 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0345	SLC39A4	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A4 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0345	SLC39A4	Co-transporter	Cholera	Co-transport of human SLC39A4 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0345	SLC39A4	Co-transporter	Septicemic plague	Co-transport of human SLC39A4 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0345	SLC39A4	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A4 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0345	SLC39A4	Co-transporter	Cholera	Co-transport of human SLC39A4 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0345	SLC39A4	Sequestration substrate	.	Sequestration of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0345	SLC39A4	Sequestration substrate	.	Sequestration of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Sequestration substrate	.	Sequestration of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	.
DTD0345	SLC39A4	Sequestration substrate	.	Sequestration of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	.
DTD0345	SLC39A4	Sequestration substrate	.	Sequestration of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Sequestration substrate	.	Sequestration of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A4, which may affects its substrate/drug distribution in the body.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0345	SLC39A4	Co-transporter	.	Co-transport of human SLC39A4 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A4, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Sequestration substrate	Colon cancer	Sequestration of human SLC39A5 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0346	SLC39A5	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A5 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0346	SLC39A5	Co-transporter	Cholera	Co-transport of human SLC39A5 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0346	SLC39A5	Co-transporter	Septicemic plague	Co-transport of human SLC39A5 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0346	SLC39A5	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A5 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0346	SLC39A5	Co-transporter	Cholera	Co-transport of human SLC39A5 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0346	SLC39A5	Sequestration substrate	.	Sequestration of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0346	SLC39A5	Sequestration substrate	.	Sequestration of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Sequestration substrate	.	Sequestration of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	.
DTD0346	SLC39A5	Sequestration substrate	.	Sequestration of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	.
DTD0346	SLC39A5	Sequestration substrate	.	Sequestration of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Sequestration substrate	.	Sequestration of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A5, which may affects its substrate/drug distribution in the body.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0346	SLC39A5	Co-transporter	.	Co-transport of human SLC39A5 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A5, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Sequestration substrate	Colon cancer	Sequestration of human SLC39A6 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0347	SLC39A6	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A6 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0347	SLC39A6	Co-transporter	Cholera	Co-transport of human SLC39A6 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0347	SLC39A6	Co-transporter	Septicemic plague	Co-transport of human SLC39A6 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0347	SLC39A6	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A6 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0347	SLC39A6	Co-transporter	Cholera	Co-transport of human SLC39A6 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0347	SLC39A6	Up regulating	.	Up regulating of SLC39A6 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	O55	CD-1 mice	.	The compound Lipopolysaccharide Generated by Escherichia coli O55 has been reported to increase the expression of the drug transporter SLC39A6.	.	Liver
DTD0347	SLC39A6	Sequestration substrate	.	Sequestration of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0347	SLC39A6	Sequestration substrate	.	Sequestration of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Sequestration substrate	.	Sequestration of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	.
DTD0347	SLC39A6	Sequestration substrate	.	Sequestration of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	.
DTD0347	SLC39A6	Sequestration substrate	.	Sequestration of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Sequestration substrate	.	Sequestration of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A6, which may affects its substrate/drug distribution in the body.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Co-transporter	.	Co-transport of human SLC39A6 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A6, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0347	SLC39A6	Down regulating	.	Down regulating of SLC39A6 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by the gut microbiota and Gram negative bacteria	Host unspecified microbiota	.	C57BL/6 mice	.	The compound lipopolysaccharide generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC39A6.	.	Spleen
DTD0348	SLC39A7	Sequestration substrate	Colon cancer	Sequestration of human SLC39A7 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0348	SLC39A7	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A7 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0348	SLC39A7	Co-transporter	Cholera	Co-transport of human SLC39A7 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0348	SLC39A7	Co-transporter	Septicemic plague	Co-transport of human SLC39A7 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0348	SLC39A7	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A7 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0348	SLC39A7	Co-transporter	Cholera	Co-transport of human SLC39A7 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0348	SLC39A7	Sequestration substrate	.	Sequestration of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0348	SLC39A7	Sequestration substrate	.	Sequestration of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Sequestration substrate	.	Sequestration of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	.
DTD0348	SLC39A7	Sequestration substrate	.	Sequestration of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	.
DTD0348	SLC39A7	Sequestration substrate	.	Sequestration of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Sequestration substrate	.	Sequestration of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A7, which may affects its substrate/drug distribution in the body.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0348	SLC39A7	Co-transporter	.	Co-transport of human SLC39A7 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A7, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Sequestration substrate	Cystic fibrosis	Sequestration of human SLC39A8 substrates/drugs in cystic fibrosis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyochelin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	ATCC 15692	CD-1 mice	.	The compound Pyochelin Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	Cystic fibrosis	Sequestration of human SLC39A8 substrates/drugs in cystic fibrosis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyoverdine F-Iib	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	ATCC 15692	CD-1 mice	.	The compound Pyoverdine F-Iib Secreted by Pseudomonas aeruginosa ATCC 15692 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	Lung adenocarcinoma	Sequestration of human SLC39A8 substrates/drugs in lung adenocarcinoma condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KP20	.	Human lung adenocarcinoma cells (A549)	The compound Salmochelin SX Secreted by Klebsiella pneumoniae KP20 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	Pneumonia	Sequestration of human SLC39A8 substrates/drugs in pneumonia condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	ATCC 43816	C57BL/6 mice	.	The compound Yersiniabactin Secreted by Klebsiella pneumoniae ATCC 43816 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Co-transporter	Pneumonic plague	Co-transport of human SLC39A8 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	Upper and lower airway disease	Sequestration of human SLC39A8 substrates/drugs in upper and lower airway disease condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. equi NCTC 9682	Swiss Webster mice	.	The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	Sepsis	Sequestration of human SLC39A8 substrates/drugs in sepsis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Streptococcus suis	Streptococcus suis	serotype 9	CD-1 mice	.	The protein troA of Streptococcus suis serotype 9 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Liver
DTD0349	SLC39A8	Sequestration substrate	Colon cancer	Sequestration of human SLC39A8 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0349	SLC39A8	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A8 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0349	SLC39A8	Co-transporter	Cholera	Co-transport of human SLC39A8 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0349	SLC39A8	Co-transporter	Septicemic plague	Co-transport of human SLC39A8 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0349	SLC39A8	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A8 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0349	SLC39A8	Co-transporter	Cholera	Co-transport of human SLC39A8 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Intestine
DTD0349	SLC39A8	Up regulating	.	Up regulating of SLC39A8 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Lipopolysaccharide	Generated by Escherichia coli	Escherichia coli	O55	C57BL/6 mice	.	The compound Lipopolysaccharide Generated by Escherichia coli O55 has been reported to increase the expression of the drug transporter SLC39A8.	.	Liver
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Intestine
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KPPR1	C57BL/6 mice	.	The compound Salmochelin SX Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	KPPR1	C57BL/6 mice	.	The compound Yersiniabactin Secreted by Klebsiella pneumoniae KPPR1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	irp2	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein irp2 of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	psn	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeAB	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 2-oxoadipic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 2-oxoadipic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 2-oxoadipic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 2-oxoadipic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 2-Oxoadipic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 2-Oxoadipic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	2-Oxoadipic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 2-Oxoadipic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 3-methyl-2-oxobutanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	3-Methyl-2-oxobutanoic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 3-Methyl-2-oxobutanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound 4-methyl-2-oxopentanoic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	4-Methyl-2-oxopentanoic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound 4-Methyl-2-oxopentanoic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Aerobactin	Secreted by Escherichia coli	Escherichia coli	LG1315	.	.	The compound Aerobactin Secreted by Escherichia coli LG1315 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Achromobacter xylosoxidans	Achromobacter xylosoxidans	subsp. xylosoxydans KN 3-1	.	.	The compound Alcaligin Secreted by Achromobacter xylosoxidans subsp. xylosoxydans KN 3-1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Bordetella bronchiseptica	Bordetella bronchiseptica	B013N	.	.	The compound Alcaligin Secreted by Bordetella bronchiseptica B013N has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Alcaligin	Secreted by Bordetella pertussis	Bordetella pertussis	UT25	.	.	The compound Alcaligin Secreted by Bordetella pertussis UT25 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Anguibactin	Secreted by Vibrio anguillarum	Vibrio anguillarum	775	.	.	The compound anguibactin secreted by Vibrio anguillarum 775 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Aureochelin	Secreted by Staphylococcus aureus	Staphylococcus aureus	.	.	.	The compound aureochelin secreted by Staphylococcus aureus has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Carboxymycobactin	Secreted by Mycobacterium avium	Mycobacterium avium	CRl/69	.	.	The compound Carboxymycobactin Secreted by Mycobacterium avium CRl/69 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Cepabactin	Secreted by Burkholderia cepacia	Burkholderia cepacia	ATCC 25416	.	.	The compound Cepabactin Secreted by Burkholderia cepacia ATCC 25416 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Corynebacterium diphtheriae	Corynebacterium diphtheriae	C7 (beta)	.	.	The compound Corynebactin Secreted by Corynebacterium diphtheriae C7 (beta) has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The compound Corynebactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus thuringiensis	Bacillus thuringiensis	ATCC 33679	.	.	The compound Corynebactin Secreted by Bacillus thuringiensis ATCC 33679 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Corynebactin	Secreted by Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The compound Corynebactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	BW25113	.	.	The compound Enterobactin Secreted by Escherichia coli BW25113 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	str. K-12 substr. W3110	.	.	The compound Enterobactin Secreted by Escherichia coli str. K-12 substr. W3110 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. LT2	.	.	The compound Enterobactin Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Klebsiella pneumoniae	Klebsiella pneumoniae	298/53	.	.	The compound Enterobactin Secreted by Klebsiella pneumoniae 298/53 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Shigella sonnei	Shigella sonnei	43-GG9	.	.	The compound Enterobactin Secreted by Shigella sonnei 43-GG9 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	9.0111	.	.	The compound enterobactin secreted by Escherichia coli 9.0111 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Enterobactin	Secreted by Escherichia coli	Escherichia coli	AB33II	.	.	The compound Enterobactin Secreted by Escherichia coli AB33II has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Exochelin 772SM	Secreted by Mycolicibacterium vaccae	Mycolicibacterium vaccae	R877R	.	.	The compound Exochelin 772SM Secreted by Mycolicibacterium vaccae R877R has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine B	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine E	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine G1	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound indole-3-pyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound indole-3-pyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound indole-3-pyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound indole-3-pyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound Indole-3-pyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound Indole-3-pyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Indole-3-pyruvic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound Indole-3-pyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ornibactin	Secreted by Burkholderia cepacia	Burkholderia cepacia	TVV69	.	.	The compound Ornibactin Secreted by Burkholderia cepacia TVV69 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Petrobactin	Secreted by Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The compound Petrobactin Secreted by Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Petrobactin	Secreted by Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The compound Petrobactin Secreted by Bacillus anthracis str. Sterne has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia rustigianii	Providencia rustigianii	2	.	.	The compound phenylpyruvic acid secreted by Providencia rustigianii 2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia stuartii	Providencia stuartii	19	.	.	The compound phenylpyruvic acid secreted by Providencia stuartii 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Providencia alcalifaciens	Providencia alcalifaciens	5487	.	.	The compound phenylpyruvic acid secreted by Providencia alcalifaciens 5487 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus penneri	Proteus penneri	.	.	.	The compound phenylpyruvic acid secreted by Proteus penneri has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus mirabilis	Proteus mirabilis	NM 12	.	.	The compound Phenylpyruvic acid Secreted by Proteus mirabilis NM 12 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Proteus vulgaris	Proteus vulgaris	Ox 19	.	.	The compound Phenylpyruvic acid Secreted by Proteus vulgaris Ox 19 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Phenylpyruvic acid	Secreted by Morganella morganii	Morganella morganii	SBK3	.	.	The compound Phenylpyruvic acid Secreted by Morganella morganii SBK3 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyochelin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The compound Pyochelin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Pyoverdin	Secreted by Pseudomonas aeruginosa	Pseudomonas aeruginosa	PAO1	.	.	The compound Pyoverdin Secreted by Pseudomonas aeruginosa PAO1 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Rhizoferrin	Secreted by Rhizopus microsporus	Rhizopus microsporus	.	.	.	The compound rhizoferrin secreted by Rhizopus microsporus has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salicylic acid	Secreted by Burkholderia cepacia	Burkholderia cepacia	Pc275c	.	.	The compound Salicylic acid Secreted by Burkholderia cepacia Pc275c has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Salmochelin SX	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. LT2	.	.	The compound Salmochelin SX Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphyloferrin A	Secreted by Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The compound Staphyloferrin A Secreted by Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Staphylopine	Secreted by Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The compound Staphylopine Secreted by Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Vibriobactin	Secreted by Vibrio cholerae	Vibrio cholerae	Lou15	.	.	The compound Vibriobactin Secreted by Vibrio cholerae Lou15 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Vibriobactin	Secreted by Vibrio cholerae	Vibrio cholerae	MBG14	.	.	The compound Vibriobactin Secreted by Vibrio cholerae MBG14 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia pestis	Yersinia pestis	Yreka F1+VW+P1+P+	.	.	The compound Yersiniabactin Secreted by Yersinia pestis Yreka F1+VW+P1+P+ has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Yersiniabactin	Secreted by Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The compound Yersiniabactin Secreted by Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CaFTR1	Candida albicans	Candida albicans	.	.	.	The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	O157:H7	.	.	The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatA	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatB	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Fbp	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fec	Shigella flexneri	Shigella flexneri	2a	.	.	The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fecA	Escherichia coli	Escherichia coli	UT5600	.	.	The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Klebsiella pneumoniae	Klebsiella pneumoniae	.	.	.	The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuA	Escherichia coli	Escherichia coli	K-12	.	.	The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuB	Escherichia coli	Escherichia coli	DH5[alpha]	.	.	The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuC	Escherichia coli	Escherichia coli	AB2847	.	.	The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCBG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Streptococcus agalactiae	Streptococcus agalactiae	A909	.	.	The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Haemophilus influenzae	Haemophilus influenzae	R2866	.	.	The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD1	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN2564	.	.	The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA1	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA2	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futB	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IroA	Escherichia coli	Escherichia coli	CFT073	.	.	The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IrtAB	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mnoP	Bradyrhizobium diazoefficiens	Bradyrhizobium diazoefficiens	USDA 110	.	.	The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. zooepidemicus NCTC 7023T	.	.	The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuA	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuB	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuC	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sitA	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium JF2043	.	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sll1878	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tssS	Yersinia pseudotuberculosis	Yersinia pseudotuberculosis	YPIII	.	.	The protein tssS of Yersinia pseudotuberculosis YPIII has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM5-2031.11+	.	.	The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Sequestration substrate	.	Sequestration of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A8, which may affects its substrate/drug distribution in the body.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0349	SLC39A8	Co-transporter	.	Co-transport of human SLC39A8 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A8, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Sequestration substrate	Colon cancer	Sequestration of human SLC39A9 substrates/drugs in colon cancer condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	Human colon adenocarcinoma cells (Caco-2)	The protein znuA of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	Colon
DTD0350	SLC39A9	Sequestration substrate	Gastroenteritis	Sequestration of human SLC39A9 substrates/drugs in gastroenteritis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni 81-176	Chicken	.	The protein znuA of Campylobacter jejuni subsp. jejuni 81-176 has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	Jejunum
DTD0350	SLC39A9	Co-transporter	Cholera	Co-transport of human SLC39A9 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZnuABC of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0350	SLC39A9	Co-transporter	Septicemic plague	Co-transport of human SLC39A9 substrates/drugs in septicemic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein ZnuABC of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0350	SLC39A9	Sequestration substrate	Bacterial meningitis	Sequestration of human SLC39A9 substrates/drugs in bacterial meningitis condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuD	Neisseria meningitidis	Neisseria meningitidis	B16B6	C57BL/6 mice	.	The protein ZnuD of Neisseria meningitidis B16B6 has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	Brain
DTD0350	SLC39A9	Co-transporter	Cholera	Co-transport of human SLC39A9 substrates/drugs in cholera condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZrgABCDE	Vibrio cholerae	Vibrio cholerae	C6706	CD-1 mice	.	The protein ZrgABCDE of Vibrio cholerae C6706 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	Small intestine
DTD0350	SLC39A9	Sequestration substrate	.	Sequestration of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zinA	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein zinA of Listeria monocytogenes EGD-e has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	Uterus
DTD0350	SLC39A9	Sequestration substrate	.	Sequestration of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	Brucella abortus	Brucella abortus	544	BALB/c athymic Nu/Nu mice	Human human papillomavirus-related endocervical adenocarcinoma cells (HeLa)	The protein znua of Brucella abortus 544 has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	Cervix
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium IR715	C57BL/6 mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium IR715 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	BALB/c mice	.	The protein ZnuABC of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Pasteurella multocida	Pasteurella multocida	PM25	Swiss mice	.	The protein ZnuABC of Pasteurella multocida PM25 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZurAM	Listeria monocytogenes	Listeria monocytogenes	EGD-e	MF1 mice	Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)	The protein ZurAM of Listeria monocytogenes EGD-e has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	Uterus
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcCBA	Streptococcus pneumoniae	Streptococcus pneumoniae	D39	.	.	The protein AdcCBA of Streptococcus pneumoniae D39 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	AdcRCBA	Streptococcus gordonii	Streptococcus gordonii	str. Challis	.	.	The protein AdcRCBA of Streptococcus gordonii str. Challis has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CzrA	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein czra of Staphylococcus aureus has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Sequestration substrate	.	Sequestration of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	.
DTD0350	SLC39A9	Sequestration substrate	.	Sequestration of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ycdH	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein ycdH of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	.
DTD0350	SLC39A9	Sequestration substrate	.	Sequestration of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	yciC	Bacillus subtilis	Bacillus subtilis	ZB307A	.	.	The protein yciC of Bacillus subtilis ZB307A has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZitSQP	Lactococcus lactis	Lactococcus lactis	subsp. lactis Il1403	.	.	The protein ZitSQP of Lactococcus lactis subsp. lactis Il1403 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Sequestration substrate	.	Sequestration of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	znuA	[Haemophilus] ducreyi	[Haemophilus] ducreyi	35000HP	.	.	The protein znuA of [Haemophilus] ducreyi 35000HP has been reported to sequester the substrate/drug of SLC39A9, which may affects its substrate/drug distribution in the body.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Escherichia coli	Escherichia coli	SB2847	.	.	The protein ZnuABC of Escherichia coli SB2847 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZnuABC	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 17978	.	.	The protein ZnuABC of Acinetobacter baumannii ATCC 17978 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfA	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfA of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfB	Aspergillus fumigatus	Aspergillus fumigatus	CETC	.	.	The protein zrfB of Aspergillus fumigatus CETC has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	zrfC	Aspergillus fumigatus	Aspergillus fumigatus	CEA17	.	.	The protein zrfC of Aspergillus fumigatus CEA17 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	.	.	.	The protein zrt1 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT1	Candida albicans	Candida albicans	M134	.	.	The protein ZRT1 of Candida albicans M134 has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0350	SLC39A9	Co-transporter	.	Co-transport of human SLC39A9 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ZRT2	Candida albicans	Candida albicans	.	.	.	The protein zrt2 of Candida albicans has been reported to transport similar substrates/drugs of SLC39A9, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC40A1 expression in conventional mice compared with germ-free mice	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	1,3-Diaminopropane	Generated by Lactobacillus reuteri	Limosilactobacillus reuteri	MM4-1A	C57BL/6 germ-free mice	Human colon carcinoma cells (HCT-116)	The compound 1,3-Diaminopropane Generated by Limosilactobacillus reuteri MM4-1A has been reported to decrease the expression of the drug transporter SLC40A1.	.	Duodenum
DTD0353	SLC40A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC40A1 expression in conventional mice compared with germ-free mice	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	3-Hydroxypropanal	Generated by Lactobacillus reuteri	Limosilactobacillus reuteri	MM4-1A	C57BL/6 germ-free mice	Human colon carcinoma cells (HCT-116)	The compound 3-Hydroxypropanal Generated by Limosilactobacillus reuteri MM4-1A has been reported to decrease the expression of the drug transporter SLC40A1.	.	Duodenum
DTD0353	SLC40A1	Co-transporter	Pneumonic plague	Co-transport of human SLC40A1 substrates/drugs in pneumonic plague condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein feo of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0353	SLC40A1	Sequestration substrate	Upper and lower airway disease	Sequestration of human SLC40A1 substrates/drugs in upper and lower airway disease condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. equi NCTC 9682	Swiss Webster mice	.	The protein mtsB of Streptococcus equi subsp. equi NCTC 9682 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fepD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	C3H/HeOuJ mice	.	The protein fepD of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	Intestine
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	psn	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein psn of Yersinia pestis KIM5 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	Lung
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Sit1p	Candida albicans	Candida albicans	CAF2-1	BALB/c mice	.	The protein Sit1p of Candida albicans CAF2-1 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeAB	Yersinia pestis	Yersinia pestis	KIM5	Swiss Webster mice	.	The protein YfeAB of Yersinia pestis KIM5 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	Blood
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM6	Swiss Webster mice	.	The protein YfeABCD of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	Lung
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Desferriexochelin 772MS	Secreted by Mycobacterium tuberculosis	Mycobacterium tuberculosis	str. Erdman	.	.	The compound Desferriexochelin 772MS Secreted by Mycobacterium tuberculosis str. Erdman has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine B	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine B Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine E	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine E Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Ferrioxamine G1	Secreted by Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The compound Ferrioxamine G1 Secreted by Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CaFTR1	Candida albicans	Candida albicans	.	.	.	The protein caftr1 of Candida albicans has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein cfrB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	cfrB	Campylobacter coli	Campylobacter coli	W13A	.	.	The protein cfrB of Campylobacter coli W13A has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ctuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein ctuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	desA1	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein desA1 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeO	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeO of Escherichia coli Nissle 1917 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	O157:H7	.	.	The protein efeU of Escherichia coli O157:H7 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	efeU	Escherichia coli	Escherichia coli	Nissle 1917	.	.	The protein efeU of Escherichia coli Nissle 1917 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatA	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fata of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fatB	Vibrio anguillarum	Vibrio anguillarum	775	.	.	The protein fatb of Vibrio anguillarum 775 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Fbp	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein Fbp of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fec	Shigella flexneri	Shigella flexneri	2a	.	.	The protein fec of Shigella flexneri 2a has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fecA	Escherichia coli	Escherichia coli	UT5600	.	.	The protein fecA of Escherichia coli UT5600 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feo	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein feo of Vibrio cholerae O395 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoA	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoA of Escherichia coli str. K-12 substr. MC4100 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein feoB of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein feoB of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Escherichia coli	Escherichia coli	str. K-12 substr. MC4100	.	.	The protein feoB of Escherichia coli str. K-12 substr. MC4100 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoB of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein feoC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	feoC	Klebsiella pneumoniae	Klebsiella pneumoniae	.	.	.	The protein feoc of Klebsiella pneumoniae has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuA	Escherichia coli	Escherichia coli	K-12	.	.	The protein fhuA of Escherichia coli K-12 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuB	Escherichia coli	Escherichia coli	DH5[alpha]	.	.	The protein fhuB of Escherichia coli DH5[alpha] has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuC	Escherichia coli	Escherichia coli	AB2847	.	.	The protein fhuC of Escherichia coli AB2847 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCBG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein FhuCBG of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Streptococcus agalactiae	Streptococcus agalactiae	A909	.	.	The protein FhuCDB of Streptococcus agalactiae A909 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	FhuCDB	Haemophilus influenzae	Haemophilus influenzae	R2866	.	.	The protein FhuCDB of Haemophilus influenzae R2866 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein fhuD of Escherichia coli BL21(DE3) has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhuD1	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhuD1 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein fhud2 of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fhud2	Staphylococcus aureus	Staphylococcus aureus	RN2564	.	.	The protein fhud2 of Staphylococcus aureus RN2564 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA1	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa1 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futA2	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futa2 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	futB	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein futb of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	fyuA	Yersinia enterocolitica	Yersinia enterocolitica	WA-C	.	.	The protein fyuA of Yersinia enterocolitica WA-C has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	GAPDH	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein GAPDH of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	HtsABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein HtsABC of Staphylococcus aureus RN6390 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IroA	Escherichia coli	Escherichia coli	CFT073	.	.	The protein IroA of Escherichia coli CFT073 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	iroN	Escherichia coli	Escherichia coli	O18:H7	.	.	The protein iroN of Escherichia coli O18:H7 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IrtAB	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein IrtAB of Mycobacterium tuberculosis H37Rv has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	BB	.	.	The protein isdA of Staphylococcus aureus BB has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	N100	.	.	The protein isdA of Staphylococcus aureus N100 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	FA19	.	.	The protein lbpA of Neisseria gonorrhoeae FA19 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	lbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein lbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mnoP	Bradyrhizobium diazoefficiens	Bradyrhizobium diazoefficiens	USDA 110	.	.	The protein mnoP of Bradyrhizobium diazoefficiens USDA 110 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MntABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein MntABC of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mtsB	Streptococcus equi	Streptococcus equi	subsp. zooepidemicus NCTC 7023T	.	.	The protein mtsB of Streptococcus equi subsp. zooepidemicus NCTC 7023T has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	p19	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein p19 of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0641	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0641 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0704	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv0704 of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv1872c	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein Rv1872c of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SfaABC	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein SfaABC of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuA	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfua of Serratia marcescens has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuB	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfub of Serratia marcescens has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sfuC	Serratia marcescens	Serratia marcescens	.	.	.	The protein sfuc of Serratia marcescens has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SirABC	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus RN4220	.	.	The protein SirABC of Staphylococcus aureus subsp. aureus RN4220 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sitA	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein sitA of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Shigella flexneri	Shigella flexneri	SA100	.	.	The protein SitABCD of Shigella flexneri SA100 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SitABCD	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium JF2043	.	.	The protein SitABCD of Salmonella enterica subsp. enterica serovar Typhimurium JF2043 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sll1878	Synechocystis sp. PCC 6803	Synechocystis	sp. PCC 6803 6803	.	.	The protein sll1878 of Synechocystis sp. PCC 6803 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	SstABCD	Staphylococcus aureus	Staphylococcus aureus	W	.	.	The protein SstABCD of Staphylococcus aureus W has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbp1	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbp1 of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpa of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpA of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpA	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpa of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria gonorrhoeae	Neisseria gonorrhoeae	.	.	.	The protein tbpb of Neisseria gonorrhoeae has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Neisseria meningitidis	Neisseria meningitidis	.	.	.	The protein tbpb of Neisseria meningitidis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Haemophilus influenzae	Haemophilus influenzae	type b	.	.	The protein tbpB of Haemophilus influenzae type b has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tbpB	Moraxella catarrhalis	Moraxella catarrhalis	.	.	.	The protein tbpb of Moraxella catarrhalis has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. ATCC 14028	.	.	The protein tonB of Salmonella enterica subsp. enterica serovar Typhimurium str. ATCC 14028 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K199	.	.	The protein tonB of Pseudomonas aeruginosa K199 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	TonB1	Pseudomonas aeruginosa	Pseudomonas aeruginosa	K1040	.	.	The protein TonB1 of Pseudomonas aeruginosa K1040 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tonB3	Acinetobacter baumannii	Acinetobacter baumannii	ATCC 19606	.	.	The protein tonB3 of Acinetobacter baumannii ATCC 19606 has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	138	.	.	The protein tpn of Staphylococcus epidermidis 138 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Tpn	Staphylococcus epidermidis	Staphylococcus epidermidis	2	.	.	The protein tpn of Staphylococcus epidermidis 2 has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	troA	Treponema pallidum	Treponema pallidum	subsp. pallidum str. Nichols	.	.	The protein troA of Treponema pallidum subsp. pallidum str. Nichols has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Sequestration substrate	.	Sequestration of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	tuf	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Ra	.	.	The protein tuf of Mycobacterium tuberculosis H37Ra has been reported to sequester the substrate/drug of SLC40A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0353	SLC40A1	Co-transporter	.	Co-transport of human SLC40A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	YfeABCD	Yersinia pestis	Yersinia pestis	KIM5-2031.11+	.	.	The protein YfeABCD of Yersinia pestis KIM5-2031.11+ has been reported to transport similar substrates/drugs of SLC40A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0353	SLC40A1	Up regulating	Anemia	Up regulating of SLC40A1 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Acetate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (acetate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC40A1.	.	Duodenum
DTD0353	SLC40A1	Up regulating	Anemia	Up regulating of SLC40A1 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Butyrate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (butyrate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC40A1.	.	Duodenum
DTD0353	SLC40A1	Up regulating	Anemia	Up regulating of SLC40A1 expression in anemia condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Short-chain fatty acid (Propionate)	Dietary inulin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Yorkshire-Hampshire-Landrace hybrid pigs	.	The metabolite short-chain fatty acid (propionate) generated from the metabolism of dietary inulin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC40A1.	.	Duodenum
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Yersinia pestis	Yersinia pestis	KIM6	.	.	The protein mgtA of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein mgtA of Escherichia coli BL21(DE3) has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN1379	.	.	The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN1379 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN2540	.	.	The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN2540 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN1010	.	.	The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN1010 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN1379	.	.	The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium TN1379 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium	.	.	The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN1010	.	.	The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium TN1010 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MgtBC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein MgtBC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Thermus thermophilus	Thermus thermophilus	.	.	.	The protein mgte of Thermus thermophilus has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Providencia stuartii	Providencia stuartii	.	.	.	The protein mgte of Providencia stuartii has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0354	SLC41A1	Co-transporter	.	Co-transport of human SLC41A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Alkalihalophilus pseudofirmus	Alkalihalophilus pseudofirmus	OF4	.	.	The protein mgtE of Alkalihalophilus pseudofirmus OF4 has been reported to transport similar substrates/drugs of SLC41A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0355	SLC41A2	Co-transporter	.	Co-transport of human SLC41A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Thermus thermophilus	Thermus thermophilus	.	.	.	The protein mgte of Thermus thermophilus has been reported to transport similar substrates/drugs of SLC41A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0355	SLC41A2	Co-transporter	.	Co-transport of human SLC41A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Providencia stuartii	Providencia stuartii	.	.	.	The protein mgte of Providencia stuartii has been reported to transport similar substrates/drugs of SLC41A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0355	SLC41A2	Co-transporter	.	Co-transport of human SLC41A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Alkalihalophilus pseudofirmus	Alkalihalophilus pseudofirmus	OF4	.	.	The protein mgtE of Alkalihalophilus pseudofirmus OF4 has been reported to transport similar substrates/drugs of SLC41A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0356	SLC41A3	Co-transporter	.	Co-transport of human SLC41A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Thermus thermophilus	Thermus thermophilus	.	.	.	The protein mgte of Thermus thermophilus has been reported to transport similar substrates/drugs of SLC41A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0356	SLC41A3	Co-transporter	.	Co-transport of human SLC41A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Providencia stuartii	Providencia stuartii	.	.	.	The protein mgte of Providencia stuartii has been reported to transport similar substrates/drugs of SLC41A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0356	SLC41A3	Co-transporter	.	Co-transport of human SLC41A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtE	Alkalihalophilus pseudofirmus	Alkalihalophilus pseudofirmus	OF4	.	.	The protein mgtE of Alkalihalophilus pseudofirmus OF4 has been reported to transport similar substrates/drugs of SLC41A3, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0361	SLC43A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC43A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC43A2.	.	Jejunum
DTD0007	SLC47A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC47A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC47A1.	.	Duodenum
DTD0007	SLC47A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC47A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC47A1.	.	Jejunum
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	bhuA	Brucella abortus	Brucella abortus	2308	BALB/c athymic Nu/Nu mice	.	The protein bhua of Brucella abortus 2308 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hbpA	Haemophilus influenzae	Haemophilus influenzae	86-028NP	Sprague-Dawley rats	.	The protein hbpA of Haemophilus influenzae 86-028NP has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sbnA	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus RN4220	Swiss Webster mice	.	The protein sbnA of Staphylococcus aureus subsp. aureus RN4220 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Delta-Hemolysin	Secreted by Vibrio cholerae	Vibrio cholerae	Q20523	.	.	The compound Delta-Hemolysin Secreted by Vibrio cholerae Q20523 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CeuBC	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein CeuBC of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	chuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein chuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	chuA	Escherichia coli	Escherichia coli	O157:H7 str. EDL933	.	.	The protein chuA of Escherichia coli O157:H7 str. EDL933 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Co-transporter	.	Co-transport of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ChuABCD	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein ChuABCD of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hasA	Serratia marcescens	Serratia marcescens	SM365	.	.	The protein hasA of Serratia marcescens SM365 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hbp	Escherichia coli	Escherichia coli	EB1 (O8-K43)	.	.	The protein hbp of Escherichia coli EB1 (O8-K43) has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hhuA	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hhuA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitA	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Co-transporter	.	Co-transport of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitB	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitB of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0375	SLC48A1	Co-transporter	.	Co-transport of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitC	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitC of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hmbR	Neisseria meningitidis	Neisseria meningitidis	IR1072	.	.	The protein hmbR of Neisseria meningitidis IR1072 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hpuB	Neisseria meningitidis	Neisseria meningitidis	FAM18	.	.	The protein hpuB of Neisseria meningitidis FAM18 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	htaA	Corynebacterium diphtheriae	Corynebacterium diphtheriae	1737	.	.	The protein htaa of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	htaB	Corynebacterium diphtheriae	Corynebacterium diphtheriae	1737	.	.	The protein htab of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hutA	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein hutA of Vibrio cholerae O395 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hutA	Bartonella quintana	Bartonella quintana	JK 31	.	.	The protein hutA of Bartonella quintana JK 31 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hxuC	Haemophilus influenzae	Haemophilus influenzae	type b DL42	.	.	The protein hxuC of Haemophilus influenzae type b DL42 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ilsA	Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The protein ilsA of Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdB	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus str. Newman	.	.	The protein isdB of Staphylococcus aureus subsp. aureus str. Newman has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdC	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein isdc of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IsdDEF	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein IsdDEF of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdG of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdG	Staphylococcus lugdunensis	Staphylococcus lugdunensis	N920143	.	.	The protein isdG of Staphylococcus lugdunensis N920143 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdH	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein isdH of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdH	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein isdh of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdI	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdI of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Co-transporter	.	Co-transport of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdX1	Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The protein isdX1 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0375	SLC48A1	Co-transporter	.	Co-transport of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdX2	Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The protein isdX2 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC48A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mhuD	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein mhuD of Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0203	Mycobacterium tuberculosis	Mycobacterium tuberculosis	.	.	.	The protein rv0203 of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0375	SLC48A1	Sequestration substrate	.	Sequestration of human SLC48A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	shr	Streptococcus pyogenes	Streptococcus pyogenes	JRS4	.	.	The protein shr of Streptococcus pyogenes JRS4 has been reported to sequester the substrate/drug of SLC48A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	bhuA	Brucella abortus	Brucella abortus	2308	BALB/c athymic Nu/Nu mice	.	The protein bhua of Brucella abortus 2308 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hbpA	Haemophilus influenzae	Haemophilus influenzae	86-028NP	Sprague-Dawley rats	.	The protein hbpA of Haemophilus influenzae 86-028NP has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sbnA	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus RN4220	Swiss Webster mice	.	The protein sbnA of Staphylococcus aureus subsp. aureus RN4220 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Delta-Hemolysin	Secreted by Vibrio cholerae	Vibrio cholerae	Q20523	.	.	The compound Delta-Hemolysin Secreted by Vibrio cholerae Q20523 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CeuBC	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein CeuBC of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	chuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein chuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	chuA	Escherichia coli	Escherichia coli	O157:H7 str. EDL933	.	.	The protein chuA of Escherichia coli O157:H7 str. EDL933 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Co-transporter	.	Co-transport of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ChuABCD	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein ChuABCD of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hasA	Serratia marcescens	Serratia marcescens	SM365	.	.	The protein hasA of Serratia marcescens SM365 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hbp	Escherichia coli	Escherichia coli	EB1 (O8-K43)	.	.	The protein hbp of Escherichia coli EB1 (O8-K43) has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hhuA	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hhuA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitA	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Co-transporter	.	Co-transport of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitB	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitB of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0376	SLC49A1	Co-transporter	.	Co-transport of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitC	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitC of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hmbR	Neisseria meningitidis	Neisseria meningitidis	IR1072	.	.	The protein hmbR of Neisseria meningitidis IR1072 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hpuB	Neisseria meningitidis	Neisseria meningitidis	FAM18	.	.	The protein hpuB of Neisseria meningitidis FAM18 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	htaA	Corynebacterium diphtheriae	Corynebacterium diphtheriae	1737	.	.	The protein htaa of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	htaB	Corynebacterium diphtheriae	Corynebacterium diphtheriae	1737	.	.	The protein htab of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hutA	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein hutA of Vibrio cholerae O395 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hutA	Bartonella quintana	Bartonella quintana	JK 31	.	.	The protein hutA of Bartonella quintana JK 31 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hxuC	Haemophilus influenzae	Haemophilus influenzae	type b DL42	.	.	The protein hxuC of Haemophilus influenzae type b DL42 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ilsA	Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The protein ilsA of Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdB	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus str. Newman	.	.	The protein isdB of Staphylococcus aureus subsp. aureus str. Newman has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdC	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein isdc of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IsdDEF	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein IsdDEF of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdG of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdG	Staphylococcus lugdunensis	Staphylococcus lugdunensis	N920143	.	.	The protein isdG of Staphylococcus lugdunensis N920143 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdH	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein isdH of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdH	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein isdh of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdI	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdI of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Co-transporter	.	Co-transport of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdX1	Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The protein isdX1 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0376	SLC49A1	Co-transporter	.	Co-transport of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdX2	Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The protein isdX2 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC49A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mhuD	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein mhuD of Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0203	Mycobacterium tuberculosis	Mycobacterium tuberculosis	.	.	.	The protein rv0203 of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0376	SLC49A1	Sequestration substrate	.	Sequestration of human SLC49A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	shr	Streptococcus pyogenes	Streptococcus pyogenes	JRS4	.	.	The protein shr of Streptococcus pyogenes JRS4 has been reported to sequester the substrate/drug of SLC49A1, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	bhuA	Brucella abortus	Brucella abortus	2308	BALB/c athymic Nu/Nu mice	.	The protein bhua of Brucella abortus 2308 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hbpA	Haemophilus influenzae	Haemophilus influenzae	86-028NP	Sprague-Dawley rats	.	The protein hbpA of Haemophilus influenzae 86-028NP has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	sbnA	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus RN4220	Swiss Webster mice	.	The protein sbnA of Staphylococcus aureus subsp. aureus RN4220 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	Blood
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Compound	Delta-Hemolysin	Secreted by Vibrio cholerae	Vibrio cholerae	Q20523	.	.	The compound Delta-Hemolysin Secreted by Vibrio cholerae Q20523 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	CeuBC	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein CeuBC of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	chuA	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein chuA of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	chuA	Escherichia coli	Escherichia coli	O157:H7 str. EDL933	.	.	The protein chuA of Escherichia coli O157:H7 str. EDL933 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Co-transporter	.	Co-transport of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ChuABCD	Campylobacter jejuni	Campylobacter jejuni	subsp. jejuni NCTC 11168	.	.	The protein ChuABCD of Campylobacter jejuni subsp. jejuni NCTC 11168 has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hasA	Serratia marcescens	Serratia marcescens	SM365	.	.	The protein hasA of Serratia marcescens SM365 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hbp	Escherichia coli	Escherichia coli	EB1 (O8-K43)	.	.	The protein hbp of Escherichia coli EB1 (O8-K43) has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hhuA	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hhuA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitA	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitA of Haemophilus influenzae TN106 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Co-transporter	.	Co-transport of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitB	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitB of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0377	SLC49A2	Co-transporter	.	Co-transport of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hitC	Haemophilus influenzae	Haemophilus influenzae	TN106	.	.	The protein hitC of Haemophilus influenzae TN106 has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hmbR	Neisseria meningitidis	Neisseria meningitidis	IR1072	.	.	The protein hmbR of Neisseria meningitidis IR1072 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hpuB	Neisseria meningitidis	Neisseria meningitidis	FAM18	.	.	The protein hpuB of Neisseria meningitidis FAM18 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	htaA	Corynebacterium diphtheriae	Corynebacterium diphtheriae	1737	.	.	The protein htaa of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	htaB	Corynebacterium diphtheriae	Corynebacterium diphtheriae	1737	.	.	The protein htab of Corynebacterium diphtheriae 1737 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hutA	Vibrio cholerae	Vibrio cholerae	O395	.	.	The protein hutA of Vibrio cholerae O395 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hutA	Bartonella quintana	Bartonella quintana	JK 31	.	.	The protein hutA of Bartonella quintana JK 31 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	hxuC	Haemophilus influenzae	Haemophilus influenzae	type b DL42	.	.	The protein hxuC of Haemophilus influenzae type b DL42 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ilsA	Bacillus cereus	Bacillus cereus	ATCC 14579	.	.	The protein ilsA of Bacillus cereus ATCC 14579 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdA	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdA of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdB	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus str. Newman	.	.	The protein isdB of Staphylococcus aureus subsp. aureus str. Newman has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdC	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein isdc of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	IsdDEF	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein IsdDEF of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdG	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdG of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdG	Staphylococcus lugdunensis	Staphylococcus lugdunensis	N920143	.	.	The protein isdG of Staphylococcus lugdunensis N920143 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdH	Staphylococcus aureus	Staphylococcus aureus	subsp. aureus NCTC 8325	.	.	The protein isdH of Staphylococcus aureus subsp. aureus NCTC 8325 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdH	Staphylococcus aureus	Staphylococcus aureus	.	.	.	The protein isdh of Staphylococcus aureus has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdI	Staphylococcus aureus	Staphylococcus aureus	RN6390	.	.	The protein isdI of Staphylococcus aureus RN6390 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Co-transporter	.	Co-transport of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdX1	Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The protein isdX1 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0377	SLC49A2	Co-transporter	.	Co-transport of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	isdX2	Bacillus anthracis	Bacillus anthracis	str. Sterne	.	.	The protein isdX2 of Bacillus anthracis str. Sterne has been reported to transport similar substrates/drugs of SLC49A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mhuD	Mycobacterium tuberculosis	Mycobacterium tuberculosis	H37Rv	.	.	The protein mhuD of Mycobacterium tuberculosis H37Rv has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	Rv0203	Mycobacterium tuberculosis	Mycobacterium tuberculosis	.	.	.	The protein rv0203 of Mycobacterium tuberculosis has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0377	SLC49A2	Sequestration substrate	.	Sequestration of human SLC49A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	shr	Streptococcus pyogenes	Streptococcus pyogenes	JRS4	.	.	The protein shr of Streptococcus pyogenes JRS4 has been reported to sequester the substrate/drug of SLC49A2, which may affects its substrate/drug distribution in the body.	.	.
DTD0387	SLC4A7	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC4A7 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC4A7.	.	Duodenum
DTD0391	SLC51A	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC51A expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Large intestine
DTD0391	SLC51A	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC51A expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC51A.	.	Ileum
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Colon
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Ileum
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Colon
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Ileum
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Colon
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Ileum
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Colon
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Ileum
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Colon
DTD0391	SLC51A	Down regulating	.	Down regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51A.	.	Ileum
DTD0391	SLC51A	Up regulating	.	Up regulating of SLC51A expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	Human hepatoblastoma cells (HepG2)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC51A.	.	Liver
DTD0392	SLC51B	Up regulating	Metabolic dysfunction-associated fatty liver disease	Up regulating of SLC51B expression in metabolic dysfunction-associated fatty liver disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Akkermansia muciniphila	Akkermansia muciniphila	Akkermansia muciniphila	ATCC BAA-835	C57BL/6 mice	.	The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter SLC51B.	.	Ileum
DTD0392	SLC51B	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC51B expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC51B.	.	Large intestine
DTD0392	SLC51B	Up regulating	.	Up regulating of SLC51B expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	Human hepatoblastoma cells (HepG2)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC51B.	.	Liver
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Yersinia pestis	Yersinia pestis	KIM6	.	.	The protein mgtA of Yersinia pestis KIM6 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Escherichia coli	Escherichia coli	BL21(DE3)	.	.	The protein mgtA of Escherichia coli BL21(DE3) has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN1379	.	.	The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN1379 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN2540	.	.	The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN2540 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtA	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN1010	.	.	The protein mgtA of Salmonella enterica subsp. enterica serovar Typhimurium TN1010 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN1379	.	.	The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium TN1379 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium	.	.	The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	mgtB	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium TN1010	.	.	The protein mgtB of Salmonella enterica subsp. enterica serovar Typhimurium TN1010 has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0414	SLC58A1	Co-transporter	.	Co-transport of human SLC58A1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	MgtBC	Salmonella enterica	Salmonella enterica	subsp. enterica serovar Typhimurium str. 14028S	.	.	The protein MgtBC of Salmonella enterica subsp. enterica serovar Typhimurium str. 14028S has been reported to transport similar substrates/drugs of SLC58A1, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0418	SLC5A1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC5A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bacteroides thetaiotaomicron	Bacteroides thetaiotaomicron	Bacteroides thetaiotaomicron	.	Germ-free mice	.	The Bacteroides thetaiotaomicron has been reported to increase the expression of the drug transporter SLC5A1.	.	Intestine
DTD0418	SLC5A1	Down regulating	Gastrointestinal disturbances in children with autism	Down regulating of SLC5A1 expression in gastrointestinal disturbances expression in children with autism condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bacteroides Vulgatus isolates(down)	Bacteroides Vulgatus	Bacteroides Vulgatus	.	Children with autistic disorder and GI disease	.	The Bacteroides Vulgatus has been reported to decrease the expression of the drug transporter SLC5A1.	.	Ileum
DTD0418	SLC5A1	Down regulating	Gastrointestinal disturbances in children with autism	Down regulating of SLC5A1 expression in gastrointestinal disturbances expression in children with autism condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Faecalibacterium prausnitzii isolates	Faecalibacterium prausnitzii	Faecalibacterium prausnitzii	.	Children with autistic disorder and GI disease	.	The Faecalibacterium prausnitzii has been reported to decrease the expression of the drug transporter SLC5A1.	.	Ileum
DTD0418	SLC5A1	Inhibition	Watery diarrhea	Inhibition of SLC5A1 function in watery diarrhea condition	Class3: Biosynthesis of microbial molecules that affect transporters	Protein	eae	Generated by Escherichia coli	Escherichia coli	O127:H6 str. E2348/69	.	Human colon adenocarcinoma cells (Caco-2)	The protein eae of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC5A1.	.	Duodenum
DTD0418	SLC5A1	Inhibition	Watery diarrhea	Inhibition of SLC5A1 function in watery diarrhea condition	Class3: Biosynthesis of microbial molecules that affect transporters	Protein	espF(U)	Generated by Escherichia coli	Escherichia coli	O127:H6 str. E2348/69	.	Human colon adenocarcinoma cells (Caco-2)	The protein espF(U) of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC5A1.	.	Duodenum
DTD0418	SLC5A1	Inhibition	Watery diarrhea	Inhibition of SLC5A1 function in watery diarrhea condition	Class3: Biosynthesis of microbial molecules that affect transporters	Protein	map	Generated by Escherichia coli	Escherichia coli	O127:H6 str. E2348/69	.	Human colon adenocarcinoma cells (Caco-2)	The protein map of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC5A1.	.	Duodenum
DTD0418	SLC5A1	Inhibition	Diarrhea associated with infection by enteropathogenic Escherichia coli	Inhibition of SLC5A1 function in diarrhea associated with infection by enteropathogenic Escherichia coli condition	Class3: Biosynthesis of microbial molecules that affect transporters	Protein	tir	Generated by Escherichia coli	Escherichia coli	O127:H6 str. E2348/69	.	Human colon adenocarcinoma cells (Caco-2)	The protein tir of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC5A1.	.	Duodenum
DTD0418	SLC5A1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC5A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A1.	.	Colon
DTD0418	SLC5A1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC5A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A1.	.	Ileum
DTD0424	SLC5A4	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC5A4 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC5A4.	.	Jejunum
DTD0428	SLC5A8	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC5A8 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A8.	.	Colon
DTD0428	SLC5A8	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC5A8 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A8.	.	Ileum
DTD0428	SLC5A8	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC5A8 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Unspecified Gut microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster germ-free mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A8.	.	Ileum/colon
DTD0428	SLC5A8	Up regulating	.	Up regulating of SLC5A8 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Chenodeoxycholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	Rat small intestine epithelial cells (IEC-6)	The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC5A8.	.	Small intestine
DTD0439	SLC65A2	Up regulating	Metabolic dysfunction-associated fatty liver disease	Up regulating of SLC65A2 expression in metabolic dysfunction-associated fatty liver disease condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Akkermansia muciniphila	Akkermansia muciniphila	Akkermansia muciniphila	ATCC BAA-835	C57BL/6 mice	.	The Akkermansia muciniphila ATCC BAA-835 has been reported to increase the expression of the drug transporter SLC65A2.	.	Ileum
DTD0439	SLC65A2	Down regulating	.	Down regulating of SLC65A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Trimethylamine oxide	L-carnitine metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	.	The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC65A2.	.	Small intestine
DTD0439	SLC65A2	Down regulating	.	Down regulating of SLC65A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Trimethylamine oxide	L-carnitine metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC65A2.	.	Liver
DTD0439	SLC65A2	Down regulating	.	Down regulating of SLC65A2 expression in the health condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC65A2.	.	Small intestine
DTD0452	SLC6A2	Co-transporter	.	Co-transport of human SLC6A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	leuT	Aquifex aeolicus	Aquifex aeolicus	.	.	.	The protein leut of Aquifex aeolicus has been reported to transport similar substrates/drugs of SLC6A2, which affects the distribution of its substrate/drug in vivo.	.	.
DTD0455	SLC6A3	Up regulating	Tourette syndrome	Up regulating of SLC6A3 expression in tourette syndrome condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus plantarum	Lactiplantibacillus plantarum	Lactiplantibacillus plantarum	PS128	Sprague-Dawley rats	.	The Lactiplantibacillus plantarum PS128 has been reported to increase the expression of the drug transporter SLC6A3.	Serotonin	Brain
DTD0455	SLC6A3	Sequestration substrate	.	Sequestration of human SLC6A3 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Helicobacter pylori	Helicobacter pylori	Helicobacter pylori	ATCC 700824	.	Human gastric epithelial cells	The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC6A3, thereby affecting the efficacy, safety, or bioavailability of the drug.	L-dopamine	Stomach
DTD0455	SLC6A3	Down regulating	Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli	Down regulating of SLC6A3 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Citrobacter rodentium	Citrobacter rodentium	Citrobacter rodentium	DBS120	FVB/N mice	.	The Citrobacter rodentium DBS120 has been reported to decrease the expression of the drug transporter SLC6A3.	.	Colon
DTD0455	SLC6A3	Up regulating	Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli	Up regulating of SLC6A3 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus acidophilus	Lactobacillus acidophilus	Lactobacillus acidophilus	ATCC 4357	FVB/N mice	.	The Lactobacillus acidophilus ATCC 4357 has been reported to increase the expression of the drug transporter SLC6A3.	.	Colon
DTD0455	SLC6A3	Down regulating	Watery diarrhea	Down regulating of SLC6A3 expression in watery diarrhea condition	Class3: Biosynthesis of microbial molecules that affect transporters	Protein	espG	Generated by Escherichia coli	Escherichia coli	O127:H6 str. E2348/69	.	Human colon adenocarcinoma cells (Caco-2)	The protein espG form Escherichia coli O127:H6 str. E2348/69 has been reported to decrease the expression of the drug transporter SLC6A3.	.	Colon
DTD0455	SLC6A3	Inhibition	Watery diarrhea	Inhibition of SLC6A3 function in watery diarrhea condition	Class3: Biosynthesis of microbial molecules that affect transporters	Protein	espG2	Generated by Escherichia coli	Escherichia coli	O127:H6 str. E2348/69	.	Human colon adenocarcinoma cells (Caco-2)	The protein espG2 of Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC6A3.	.	Colon
DTD0455	SLC6A3	Down regulating	.	Down regulating of SLC6A3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Dietary food metabolite from Prevotella copri	Prevotella copri	.	Caucasian human	.	The metabolite butyrate generated from the metabolism of dietary food by the Prevotella copri has been reported to decrease the expression of the drug transporter SLC6A3.	.	Brain
DTD0455	SLC6A3	Up regulating	.	Up regulating of SLC6A3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Dietary food metabolite from Bacteroides uniformis	Bacteroides uniformis	.	Caucasian human	.	The metabolite butyrate generated from the metabolism of dietary food metabolite from Bacteroides uniformis has been reported to increase the expression of the drug transporter SLC6A3.	.	Brain
DTD0455	SLC6A3	Up regulating	.	Up regulating of SLC6A3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Dietary food metabolite from Host unspecified microbiota	Host unspecified microbiota	.	NMRI mice	.	The metabolite butyrate generated from the metabolism of dietary food by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC6A3.	.	Forebrain lateral septum
DTD0456	SLC6A4	Up regulating	Health	Up regulating of SLC6A4 expression in health condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobaccillus plantarum	Lactiplantibacillus plantarum	Lactiplantibacillus plantarum	IS-10506	Sprague-Dawley rats	.	The Lactiplantibacillus plantarum IS-10506 has been reported to increase the expression of the drug transporter SLC6A4.	Serotonin	Brain
DTD0456	SLC6A4	Up regulating	Chronic constipation	Up regulating of SLC6A4 expression in chronic constipation condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Akkermansia	Unclassified Akkermansia	Unclassified Akkermansia	.	C57BL/6J specific-pathogen-free mice	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Akkermansia has been reported to increase the expression of the drug transporter SLC6A4.	.	Colon
DTD0456	SLC6A4	Up regulating	Chronic constipation	Up regulating of SLC6A4 expression in chronic constipation condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Bacteroides	Unclassified Bacteroides	Unclassified Bacteroides	.	C57BL/6J specific-pathogen-free mice	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Bacteroides has been reported to increase the expression of the drug transporter SLC6A4.	.	Colon
DTD0456	SLC6A4	Up regulating	Chronic constipation	Up regulating of SLC6A4 expression in chronic constipation condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Clostridium coleatum(down)	Thomasclavelia cocleata	Thomasclavelia cocleata	.	C57BL/6J specific-pathogen-free mice	Human colon adenocarcinoma cells (Caco-2)	The Thomasclavelia cocleata has been reported to increase the expression of the drug transporter SLC6A4.	.	Colon
DTD0456	SLC6A4	Up regulating	Chronic constipation	Up regulating of SLC6A4 expression in chronic constipation condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Desulfovibrio(down)	Unclassified Desulfovibrio	Unclassified Desulfovibrio	.	C57BL/6J specific-pathogen-free mice	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Desulfovibrio has been reported to increase the expression of the drug transporter SLC6A4.	.	Colon
DTD0456	SLC6A4	Up regulating	Chronic constipation	Up regulating of SLC6A4 expression in chronic constipation condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus gasseri(down)	Lactobacillus gasseri	Lactobacillus gasseri	.	C57BL/6J specific-pathogen-free mice	Human colon adenocarcinoma cells (Caco-2)	The Lactobacillus gasseri has been reported to increase the expression of the drug transporter SLC6A4.	.	Colon
DTD0456	SLC6A4	Up regulating	Chronic constipation	Up regulating of SLC6A4 expression in chronic constipation condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Methylobacterium(down)	Unclassified Methylobacterium	Unclassified Methylobacterium	.	C57BL/6J specific-pathogen-free mice	Human colon adenocarcinoma cells (Caco-2)	The Unclassified Methylobacterium has been reported to increase the expression of the drug transporter SLC6A4.	.	Colon
DTD0456	SLC6A4	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC6A4 expression in conventional mice compared with germ-free mice	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Serotonin	Generated by Host unspecified microbiota	Host unspecified microbiota	.	Germ-free mice	Rat insulinoma cells (RIN14B)	The compound serotonin generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC6A4.	.	Colon
DTD0456	SLC6A4	Down regulating	.	Down regulating of SLC6A4 expression in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	Serotonin	Generated by Host unspecified microbiota	Host unspecified microbiota	.	Sprague-Dawley rats	.	The compound serotonin generated by host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC6A4.	.	Small intestine
DTD0458	SLC6A6	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC6A6 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC6A6.	.	Liver
DTD0459	SLC6A7	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC6A7 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC6A7.	.	Jejunum
DTD0460	SLC6A8	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC6A8 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC6A8.	.	Jejunum
DTD0476	SLC7A9	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLC7A9 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLC7A9.	.	Colon
DTD0482	SLC9A2	Down regulating	Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli	Down regulating of SLC9A2 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Citrobacter rodentium	Citrobacter rodentium	Citrobacter rodentium	DBS120	FVB/N mice	.	The Citrobacter rodentium DBS120 has been reported to decrease the expression of the drug transporter SLC9A2.	.	Colon
DTD0482	SLC9A2	Activation	Diarrhea associated with infection by enteropathogenic Escherichia coli	Activation of SLC9A2 membrane localization in diarrhea associated with infection by enteropathogenic Escherichia coli condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	O127:H6 str. E2348/69	.	Human colon adenocarcinoma cells (Caco-2)	The Escherichia coli O127:H6 str. E2348/69 has been reported to activate the function of the drug transporter SLC9A2.	.	Colon
DTD0482	SLC9A2	Inhibition	.	Inhibition of SLC9A2 function in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	N-Acetyl-cholera toxin peptide 3-amide	Generated by Vibrio cholerae	Vibrio cholerae	.	Sprague-Dawley rats	.	The compound n-acetyl-cholera toxin peptide 3-amide generated by Vibrio cholerae has been reported to inhibit the function of the drug transporter SLC9A2.	.	Ileum
DTD0482	SLC9A2	Inhibition	.	Inhibition of SLC9A2 function in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Protein	stx1	Generated by Escherichia coli	Escherichia coli	O157:H7	Rabbits	Human colon adenocarcinoma cells (T84)	The protein stx1 of Escherichia coli O157:H7 has been reported to inhibit the function of the drug transporter SLC9A2.	.	Colon
DTD0482	SLC9A2	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLC9A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 germ-free/conventionally-raised mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC9A2.	.	Ileum
DTD0483	SLC9A3	Down regulating	Clostridium difficile infection	Down regulating of SLC9A3 expression in clostridium difficile infection condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Clostridium difficile	Clostridioides difficile	Clostridioides difficile	.	.	.	The Clostridioides difficile has been reported to decrease the expression of the drug transporter SLC9A3.	.	Colon
DTD0483	SLC9A3	Inhibition	Diarrhea associated with infection by enteropathogenic Escherichia coli	Inhibition of SLC9A3 function in diarrhea associated with infection by enteropathogenic Escherichia coli condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	O127:H6 str. E2348/69	.	Human colon adenocarcinoma cells (Caco-2)	The Escherichia coli O127:H6 str. E2348/69 has been reported to inhibit the function of the drug transporter SLC9A3.	.	Colon
DTD0483	SLC9A3	Up regulating	Fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli	Up regulating of SLC9A3 expression in fatal diarrhea/infections with enteropathogenic E. coli/infections with enterohemorrhagic E. coli condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Lactobacillus acidophilus	Lactobacillus acidophilus	Lactobacillus acidophilus	ATCC 4357	FVB/N mice	.	The Lactobacillus acidophilus ATCC 4357 has been reported to increase the expression of the drug transporter SLC9A3.	.	Colon
DTD0483	SLC9A3	Inhibition	.	Inhibition of SLC9A3 function in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Compound	N-Acetyl-cholera toxin peptide 3-amide	Generated by Vibrio cholerae	Vibrio cholerae	.	Sprague-Dawley rats	.	The compound n-acetyl-cholera toxin peptide 3-amide generated by Vibrio cholerae has been reported to inhibit the function of the drug transporter SLC9A3.	.	Ileum
DTD0483	SLC9A3	Inhibition	.	Inhibition of SLC9A3 function in the health condition	Class3: Biosynthesis of microbial molecules that affect transporters	Protein	tcdB	Generated by Clostridioides difficile	Clostridioides difficile	.	.	Pig kidney epithelial cells (LLC-PK1)	The protein tcdb generated by Clostridioides difficile has been reported to inhibit the function of the drug transporter SLC9A3.	.	Kidney
DTD0483	SLC9A3	Up regulating	.	Up regulating of SLC9A3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Butyrate	Pectin metabolite from Host unspecified microbiota	Host unspecified microbiota	.	Rats	Human colon adenocarcinoma cells (C2bbe1)	The metabolite butyrate generated from the metabolism of pectin by the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC9A3.	.	Colon
DTD0029	SLCO1A2	Sequestration substrate	.	Sequestration of human SLCO1A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Bacteroides uniformis	Bacteroides uniformis	Bacteroides uniformis	CL03T00C23	.	.	The Bacteroides uniformis CL03T00C23 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0029	SLCO1A2	Sequestration substrate	.	Sequestration of human SLCO1A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Bifidobacterium animalis subsp. lactis	Bifidobacterium animalis	Bifidobacterium animalis	subsp. lactis Bi-07	.	.	The Bifidobacterium animalis subsp. lactis Bi-07 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0029	SLCO1A2	Sequestration substrate	.	Sequestration of human SLCO1A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Bifidobacterium longum subsp. infantis	Bifidobacterium longum	Bifidobacterium longum	subsp. infantis	.	.	The Bifidobacterium longum subsp. infantis has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0029	SLCO1A2	Sequestration substrate	.	Sequestration of human SLCO1A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Clostridium bolteae	Enterocloster bolteae	Enterocloster bolteae	WAL 16351	.	.	The Enterocloster bolteae WAL 16351 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0029	SLCO1A2	Sequestration substrate	.	Sequestration of human SLCO1A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Clostridium saccharolyticum	Lacrimispora saccharolytica	Lacrimispora saccharolytica	WM1	.	.	The Lacrimispora saccharolytica WM1 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0029	SLCO1A2	Sequestration substrate	.	Sequestration of human SLCO1A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Escherichia coli	Escherichia coli	Escherichia coli	str. K-12 substr. MG1655	.	.	The Escherichia coli str. K-12 substr. MG1655 has been reported to sequester the drug Ciprofloxacin, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO1A2, thereby affecting the efficacy, safety, or bioavailability of the drug.	Ciprofloxacin	.
DTD0029	SLCO1A2	Co-transporter	.	Co-transport of human SLCO1A2 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Protein	ompF	Escherichia coli	Escherichia coli	JM712	.	.	The protein ompF of Escherichia coli JM712 has been reported to transport similar substrates/drugs of SLCO1A2, which affects the distribution of its substrate/drug in vivo.	Norfloxacin	.
DTD0029	SLCO1A2	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLCO1A2 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	Swiss Webster mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLCO1A2.	.	Liver
DTD0029	SLCO1A2	Up regulating	.	Up regulating of SLCO1A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.	.	Liver
DTD0029	SLCO1A2	Up regulating	.	Up regulating of SLCO1A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.	.	Liver
DTD0029	SLCO1A2	Up regulating	.	Up regulating of SLCO1A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.	.	Liver
DTD0029	SLCO1A2	Up regulating	.	Up regulating of SLCO1A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.	.	Liver
DTD0029	SLCO1A2	Up regulating	.	Up regulating of SLCO1A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1A2.	.	Liver
DTD0029	SLCO1A2	Down regulating	.	Down regulating of SLCO1A2 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Trimethylamine oxide	L-carnitine metabolite from Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6J mice	.	The metabolite trimethylamine oxide generated from the metabolism of l-carnitine by the host unspecified microbiota has been reported to decrease the expression of the drug transporter SLCO1A2.	.	Liver
DTD0008	SLCO1B1	Up regulating	.	Up regulating of SLCO1B1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.	.	Liver
DTD0008	SLCO1B1	Up regulating	.	Up regulating of SLCO1B1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.	.	Liver
DTD0008	SLCO1B1	Up regulating	.	Up regulating of SLCO1B1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.	.	Liver
DTD0008	SLCO1B1	Up regulating	.	Up regulating of SLCO1B1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.	.	Liver
DTD0008	SLCO1B1	Up regulating	.	Up regulating of SLCO1B1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.	.	Liver
DTD0008	SLCO1B1	Up regulating	.	Up regulating of SLCO1B1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Dehydrolithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	PXR mice	Mouse embryo embryonic stem cells (ES-R1)	The metabolite dehydrolithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.	.	Liver
DTD0008	SLCO1B1	Up regulating	.	Up regulating of SLCO1B1 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Lithocholic acid	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	IQI mice	.	The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B1.	.	Liver
DTD0030	SLCO1B3	Up regulating	.	Up regulating of SLCO1B3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Chenodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (chenodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.	.	Liver
DTD0030	SLCO1B3	Up regulating	.	Up regulating of SLCO1B3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Cholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (cholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.	.	Liver
DTD0030	SLCO1B3	Up regulating	.	Up regulating of SLCO1B3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Deoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (deoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.	.	Liver
DTD0030	SLCO1B3	Up regulating	.	Up regulating of SLCO1B3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Hyodeoxycholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (hyodeoxycholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.	.	Liver
DTD0030	SLCO1B3	Up regulating	.	Up regulating of SLCO1B3 expression in the health condition	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Bile acid (Lithocholic acid)	Metabolite from Host unspecified microbiota	Host unspecified microbiota	.	.	.	The metabolite bile acid (lithocholic acid) generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO1B3.	.	Liver
DTD0500	SLCO2A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLCO2A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLCO2A1.	.	Large intestine
DTD0500	SLCO2A1	Down regulating	Conventional mice compared with germ-free mice	Down regulating of SLCO2A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to decrease the expression of the drug transporter SLCO2A1.	.	Jejunum
DTD0500	SLCO2A1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLCO2A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO2A1.	.	Liver
DTD0031	SLCO2B1	Up regulating	Health	Up regulating of SLCO2B1 expression in health condition	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Escherichia coli Nissle 1917	Escherichia coli	Escherichia coli	Nissle 1917	Sprague-Dawley rats	.	The Escherichia coli Nissle 1917 has been reported to increase the expression of the drug transporter SLCO2B1.	Amiodarone	Intestine
DTD0031	SLCO2B1	Sequestration substrate	.	Sequestration of human SLCO2B1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Bacteroides uniformis	Bacteroides uniformis	Bacteroides uniformis	CL03T00C23	.	.	The Bacteroides uniformis CL03T00C23 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0031	SLCO2B1	Sequestration substrate	.	Sequestration of human SLCO2B1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Bifidobacterium animalis subsp. lactis	Bifidobacterium animalis	Bifidobacterium animalis	subsp. lactis Bi-07	.	.	The Bifidobacterium animalis subsp. lactis Bi-07 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0031	SLCO2B1	Sequestration substrate	.	Sequestration of human SLCO2B1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Bifidobacterium longum subsp. infantis	Bifidobacterium longum	Bifidobacterium longum	subsp. infantis	.	.	The Bifidobacterium longum subsp. infantis has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0031	SLCO2B1	Sequestration substrate	.	Sequestration of human SLCO2B1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Clostridium bolteae	Enterocloster bolteae	Enterocloster bolteae	WAL 16351	.	.	The Enterocloster bolteae WAL 16351 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0031	SLCO2B1	Sequestration substrate	.	Sequestration of human SLCO2B1 substrates/drugs in the health condition	Class1: Microbial sequestration and bioaccumulation of drugs	Interaction	Clostridium saccharolyticum	Lacrimispora saccharolytica	Lacrimispora saccharolytica	WM1	.	.	The Lacrimispora saccharolytica WM1 has been reported to sequester the drug Montelukast, which limits the distribution of the drug in the body and its binding to the drug transporter SLCO2B1, thereby affecting the efficacy, safety, or bioavailability of the drug.	Montelukast	.
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	1,7-Diamino-8-naphthol-3,6-disulphonic acid	D&C Red No. 33 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 1,7-diamino-8-naphthol-3,6-disulphonic acid generated from the metabolism of d&c red no.33 by the host unspecified microbiota has been reported to reduce the ability of D&C Red No.33 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	1-Amino-2-naphthol-6-sulfonic acid	FD&C Red No. 40 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 1-amino-2-naphthol-6-sulfonic acid generated from the metabolism of fd&c red no.40 by the host unspecified microbiota has been reported to reduce the ability of FD&C Red No.40 to inhibit drug transporters SLCO2B1.	Fexofenadine; Estrone sulfate	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	1-Amino-2-naphthol-6-sulfonic acid	FD&C Yellow No. 6 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 1-amino-2-naphthol-6-sulfonic acid generated from the metabolism of fd&c yellow no.6 by the host unspecified microbiota has been reported to reduce the ability of FD&C Yellow No.6 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	2,4-Diaminoresorcinol	D&C Brown No. 1 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 2,4-diaminoresorcinol generated from the metabolism of d&c brown no.1 by the host unspecified microbiota has been reported to reduce the ability of D&C Brown No.1 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	2-Amino-5-methylbenzenesulfonic acid	D&C Red No. 6 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 2-amino-5-methylbenzenesulfonic acid generated from the metabolism of d&c red no.6 by the host unspecified microbiota has been reported to reduce the ability of D&C Red No.6 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	4-Amino-3-hydroxy-2-naphthoic acid	D&C Red No. 6 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 4-amino-3-hydroxy-2-naphthoic acid generated from the metabolism of d&c red no.6 by the host unspecified microbiota has been reported to reduce the ability of D&C Red No.6 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	4-Amino-5-methoxy-2-methylbenzenesulfonic acid	FD&C Red No. 40 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 4-amino-5-methoxy-2-methylbenzenesulfonic acid generated from the metabolism of fd&c red no.40 by the host unspecified microbiota has been reported to reduce the ability of FD&C Red No.40 to inhibit drug transporters SLCO2B1.	Fexofenadine; Estrone sulfate	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	4-Nitroaniline	Naphthol Blue Black metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 4-nitroaniline generated from the metabolism of naphthol blue black by the host unspecified microbiota has been reported to reduce the ability of Naphthol Blue Black to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	5-Amino-2,4-dimethylbenzenesulfonic acid	FD&C Red No. 4 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite 5-amino-2,4-dimethylbenzenesulfonic acid generated from the metabolism of fd&c red no.4 by the host unspecified microbiota has been reported to reduce the ability of FD&C Red No.4 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Aniline	D&C Red No. 33 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite aniline generated from the metabolism of d&c red no.33 by the host unspecified microbiota has been reported to reduce the ability of D&C Red No.33 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Aniline	Naphthol Blue Black metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite aniline generated from the metabolism of naphthol blue black by the host unspecified microbiota has been reported to reduce the ability of Naphthol Blue Black to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Sulfanilic acid	D&C Brown No. 1 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite sulfanilic acid generated from the metabolism of d&c brown no.1 by the host unspecified microbiota has been reported to reduce the ability of D&C Brown No.1 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0031	SLCO2B1	Attenuated inhibition	Conventional mice compared with germ-free mice	Attenuated inhibition function of SLCO2B1 in conventional mice compared with germ-free mice	Class2: Microbial biotransformation of exogenous substances that interact with drug transporters	Compound	Sulfanilic acid	FD&C Yellow No. 6 metabolite from Host unspecified microbiota	Host unspecified microbiota	.	BALB/c germ-free mice	Human kidney human embryonic kidney 293 cells (HEK 293)	The metabolite sulfanilic acid generated from the metabolism of fd&c yellow no.6 by the host unspecified microbiota has been reported to reduce the ability of FD&C Yellow No.6 to inhibit drug transporters SLCO2B1.	4'-5'-Dibromofluorescein	Kidney
DTD0501	SLCO3A1	Up regulating	Conventional mice compared with germ-free mice	Up regulating of SLCO3A1 expression in conventional mice compared with germ-free mice	Class4: Microbial control of host DT expression and/or protein levels by unclear mechanisms	Interaction	Host unspecified microbiota	Host unspecified microbiota	Host unspecified microbiota	.	C57BL/6 mice	.	The host unspecified microbiota has been reported to increase the expression of the drug transporter SLCO3A1.	.	Jejunum